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There has been a growing epidemic of human papillomavirus (HPV)-induced 
oropharyngeal squamous cell carcinoma (OPSCC) for the last few decades. This is an 
underappreciated disease that can have a devastating effect on the lives of otherwise healthy young 
patients. Patients with HPV-positive OPSCC generally have a good prognosis, but still 20-30% 
fail to respond to therapy or later recur for unknown reasons. Our hypothesis is that the type of 
interactions between viral DNA and the human host DNA may determine a patient’s disease 
progression. HPV can remain its circular episomal shape, but often linearizes and integrates into 
the human genome, either into intergenic loci or into genes. The process of HPV integration is of 
particular interest as a potential driver of HPV-positive OPSCC because it is thought to be a marker 
of disease progression in cervical cancer and is reported in a large proportion of head and neck 
tumors with estimates ranging from 50-70%.  
Integration can lead to large structural variations, disrupt cellular genes and alter gene 
expression both locally and genome wide, but the exact effects of HPV integration on OPSCC 
progression are unclear. Previous studies that assessed survival differences between HPV 
integration positive versus negative patients demonstrated mixed results, so we aimed to clarify 
whether this process impacts patient outcomes. Using a polymerase chain reaction (PCR)-based 
approach, we found that HPV-positive, integration-positive patients had higher levels of the HPV 
oncogenes E6/E7 and a survival advantage over HPV-positive, integration-negative patients. The 
underlying mechanism for this improved outcome is unclear, but this work provides evidence that 
HPV integration could serve as a prognostic biomarker. 
 xvi 
We also utilized this methodology to investigate the clonal nature of HPV integration 
events, as it is clear that this process affects cell biology given the survival differences we 
discovered, but how cells containing these viral-human fusions may be selected for during tumor 
evolution is unclear. We explored the clonality of integration events in bilateral HPV+ tonsillar 
tumors and found evidence that these tumors often form as a result of clonal expansion from one 
tonsil to another given that we found shared integration sites across samples. These results indicate 
that integration events provide a survival advantage to tumor cells which are then selected for and 
expanded such that they are able to metastasize elsewhere.  
Finally, to overcome limitations of previous integration calling methodologies, we 
optimized a new targeted capture sequencing and analysis pipeline called SearcHPV. Through 
integrated analysis of HPV+ models by SearcHPV and genome-wide linked read sequencing, we 
demonstrated that HPV integration sites were found not only adjacent to known cancer-related 
genes such as TP63 and MYC, but also near regions of large structural variation in the tumor 
genome. Further, analysis of SearcHPV-assembled junction contigs demonstrated that the tool can 
be used to accurately identify viral-host junction sequences and showed that viral integration 
occurs through a variety of DNA repair mechanisms including non-homologous end joining, 
alternative end joining and microhomology mediated repair. Together, these studies highlight HPV 
genomic integration as an important contributor to cancer progression, and with new tools 
available, we believe the field is now primed to make major advances in the understanding of 
HPV-driven pathogenesis, some of which may lead to the development of novel biomarkers and/or 
treatment paradigms.  
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Human papillomaviruses (HPV) are double-stranded, small DNA viruses transmitted 
through sexual contact that infect human epithelium in anogenital and oral mucosa. There are more 
than 200 HPV types described with varying epithelial tropism and associated conditions [1].  
Infection with one or more HPV strains is nearly ubiquitous in sexually active persons.  These 
infections are usually asymptomatic and clear spontaneously. However, persistent infections may 
lead to a variety of HPV-mediated diseases, including skin warts, genital warts, precancers, cancers 
of cervix, anus, penis, vulva, vagina, and head and neck-particularly cancers of the oropharynx 
[2].  
The investigation of human papillomavirus as a potential cause of warts and cancers has 
been ongoing for centuries. The infectious nature of skin and genital warts has been described 
dating back to the ancient Greek and Roman cultures, but their viral nature wasn’t clear until the 
mid-1900s [3]. An Italian physician Rigoni-Stern noted in 1842 that cervical cancer occurred 
frequently in married women and prostitutes but almost never in nuns, leading him to conclude 
development of cervical cancer was related to an infection acquired during sexual contact [4]. 
Studies of rabbit papillomaviruses in cottontail and domestic rabbits in the mid-1900s 
demonstrated the carcinogenic potential of these viruses and helped inspire interest in studying 
human papillomaviruses in the context of cancer [5-7]. The first description of the double-stranded 
circular DNA structure of HPV was published in 1965 [8, 9]. zur Hausen began investigating the 
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potential role of HPV in cervical cancer in 1972 based on anecdotal evidence of malignant 
conversion of genital warts into squamous carcinomas, and later, he and others described novel 
HPV types in genital warts and laryngeal papillomas (HPV6 and HPV11) as well as cervical 
cancers (HPV16 and HPV18) [10-12]. A large-scale epidemiological study examining the 
association of cervical cancer and HPV in nearly 10,000 samples was first published in 1987 [13]. 
During this same time period, it was noted that women with cervical cancer had an increased risk 
for development of oral cancer, suggesting that HPV may also play an important role in head and 
neck cancer [14]. Loning and de Villiers described in 1985 the first reports of specific HPV types 
in oropharyngeal cancers [15, 16]. Larger studies examining the rates of HPV positivity in 
oropharynx cancer have since been published, estimating an HPV-positivity rate of between 25-
60% [17-20].  
Association with Disease 
Human papillomaviruses are part of the Papillomaviridae family and are grouped into six 
genera based on homology in the L1 open reading frame (ORF), which encodes for the viral capsid 
protein that coats the virus [21]. These genera are known as alpha, beta, gamma, delta, mu and nu; 
each member of a given genus has at least 40% homology. These genera are further grouped by 
HPV species, which share 60-70% L1 homology, as well as common features and epithelial 
tropism. HPVs are then distinguished by type, of which there are over 200 currently classified. 
Each HPV type is at least 10% different in L1 sequence from its closest neighbors.  
The alpha-papillomaviruses infect human mucosal and cutaneous epithelium and contain 
HPV types that are implicated in both benign and malignant lesions [22]. A subset of 14 mucosal 
HPV types within this genus is considered high-risk (hrHPV) based on their frequent association 
with various cancers and transforming ability in model systems. This includes HPV types 16, 18, 
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31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 [23]. These hrHPV types have been reported as 
the causative factor not only in cervical and oropharynx cancers but in other cancer types as well, 
including penile, anal, vulvar, and vaginal cancers [2]. hrHPV has also been reported in cases of 
esophageal [24, 25], colon [26, 27], bladder [28], prostate [29], ovarian [30, 31], breast [32], and 
lung cancers [33], but the role of HPV in these cancer types is unclear and is not currently 
recognized as causative by the International Agency for Research on Cancer [23]. hrHPV types 16 
and 18 are known to cause the majority of cervical and oropharyngeal cancers [34, 35]. Among 
oropharynx cancers studied at the University of Michigan, roughly 90% are associated with 
HPV16 and 10% are associated with other hrHPV types [36]. Despite their association with cancer, 
the majority of individuals infected with a hrHPV type will not develop cancer and will clear the 
infection [37]. 
Another subset of HPV types is considered potentially high-risk based on association with 
cancers, but evidence demonstrating carcinogenicity is lacking, for example HPV types 26 and 53 
[38]. Additional HPV types are considered low-risk (lrHPV) because they are primarily associated 
with benign lesions, genital warts and laryngeal papillomas rather than invasive neoplasias (HPV 
6, 11, 42, 43, 44) [22]. However, lrHPVs can sometimes induce non-melanoma skin cancers in 
immunocompromised individuals, including those with severe combined immunodeficiency 
(SCID), epidermodysplasia verruciformis (EV), or organ transplant recipients [39, 40].  Rare cases 
of larynx, lung, nasopharynx, and sinonasal cancer after genomic integration of lrHPV types 6 and 
11 have also been reported [41-44]. 
HPV Biology 
HPV16 is involved in the majority of HPV+ head and neck cancers. The HPV16 genome 
is a 7.9 kilobase (kb) circular genome organized into an upstream regulatory region (URR), 6 early 
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region genes (E1, E2, E4, E5, E6, E7) and 2 late region genes (L1, L2) (Figure 1.1). The process 
of an HPV infection begins with microtraumas in the epithelium that allow HPV virions to enter 
and infect the basal epithelium [45]. In the oral cavity, HPV virions most frequently infect the 
basal cells in tonsillar crypts [46]. Once within the cell, HPV is dependent on the host cell for 
replication. The viral proteins manipulate cellular pathways for viral genome 
replication/amplification and coordinate these processes with the cellular differentiation pathway, 
timing viral capsid production with the later stages of epithelial differentiation. As the 
differentiated cells reach the surface, HPV episomes are packaged and released.  
Early in an infection, the HPV oncoproteins E6 and E7 induce host cell replication by 
blocking the function of key cell cycle regulators, TP53 and RB1 (Figure 1.2). The HPV 
oncoprotein E6 recruits the cellular E3 ubiquitin ligase, E6 associated protein (E6AP), and binds 
TP53, leading to TP53 polyubiquitination and subsequent degradation by the 26S proteasome [47, 
48]. The destruction of TP53 results in failure of cell cycle arrest and apoptosis, contributing to 
unrestricted host cell growth and proliferation. The E6 gene can be expressed as full length or 
Viral 
oncoproteins-















Figure 1.1. HPV16 Genome Structure.
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alternatively spliced forms, referred to as E6*I, E6*II, or E6*III. These alternate transcripts are 
thought to be drivers of oncogenic transformation and are expressed at higher levels than full 
length E6 in tumors samples and cell lines [49]. 
HPV E7 protein sequesters and disrupts the function of the cell cycle regulator RB. In 
normal cells, RB binds the transcription factor E2F, preventing cell cycle progression. When cell 
growth signaling occurs, expression of cyclin D1 is initiated. Cyclin D1 activates cyclin dependent 
kinase (CDK)4/6, leading to monophosphorylation of RB. CDK2 is then activated by Cyclin E 
and further phosphorylates RB, releasing E2F and initiating transcription of cell cycle entry genes.  
E2F also activates transcription of p16INK4a (CDKN2A, an inhibitor of cyclin dependent kinase 
4 and the off signal for RB phosphorylation), shutting off RB phosphorylation. Ubiquitous 
phosphatase activity dephosphorylates RB, which re-sequesters E2F and stops cell cycle entry.  In 
the presence of HPV, E7 binds to the pocket of RB, disrupting the interaction with E2F. When 
E2F is liberated, it leads to continual transcription of S-phase genes, driven by other cell cycle 
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Figure 1.2. Function of HPV oncoproteins to block cell cycle regulators (A) p53 and (B) Rb.
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useful surrogate histological marker of HPV infection. The binding of E7 to RB leads to 
unscheduled continuous cell cycle entry, progression and cellular proliferation [50].  
The hrHPV E1 and E2 genes also play an essential role in viral replication; E2 recruits E1, 
which acts as a viral DNA helicase, to the replication origin in the URR [51]. This allows for the 
replication of hundreds of viral copies. Additionally, through its recruitment of cellular factors to 
the URR, E2 acts a transcriptional repressor of E6 and E7; this negative feedback loop allows for 
the coordination of the viral life cycle with the cellular differentiation process [51]. The later 
expression of L1 and L2 in the uppermost layers of the epithelium allows for packaging, assembly 
and release of the virus [52]. In most cases, the infection will become latent within 1-2 years, but 
some people will have a persistent HPV infection which can lead to the development of precancers 
or cancers. Persistent HPV infection that leads to carcinoma is characterized by high expression 
of E6 and E7 and frequent loss of E2, leading to unregulated expression of E6 and E7, which 
promotes genomic instability, oncogenic transformation, and clonal expansion [53].  
Oral Infection Epidemiology 
Although HPV is one of the most common sexually transmitted infections, persistent oral 
HPV infections are relatively rare in the normal population. Data from the National Health and 
Nutrition Examination Survey showed that the prevalence of oral HPV infection in the United 
States is approximately 4-6% [46, 54]. There are many factors associated with increased risk of 
oral HPV infection, including age, sex, race, vaccination status, number of sexual partners, and 
current smoking habits. Oral HPV infections in women peak in prevalence around ages 25 and 55, 
following a bimodal pattern. In men, risk of infection increases with age, peaking at age 60. Men 
are more likely to be infected, and higher numbers of sexual partners and smoking are associated 
with increased risk of infection. Race also plays a factor; white women are less likely to have an 
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oral infection than women of other races, and black men were more likely to have an infection. 
Asian people of both sexes living in the U.S. have lower infections than white men and women. 
Men and women who receive the quadrivalent HPV vaccine are protected against both oral and 
genital infections of HPV 6, 11, 16 and 18 but not necessarily all HPV types [54].  
Most HPV infections are naturally cleared, but in women, it has been well established that 
persistence of a genital HPV infection is a significant risk factor for developing cervical squamous 
cell carcinoma [55, 56]. However, the factors that contribute to persistent oral infection and the 
natural history of oral HPV infections leading to cancer have still not been well characterized.  
Head and Neck Squamous Cell Carcinoma 
Etiology 
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of cancers 
that arise in the mucosal lining of the upper aerodigestive tract. As a whole, HNSCC accounts for 
650,000 cancer cases and 330,000 deaths annually worldwide [57]. In the United States, HNSCC 
accounts for approximately 4% of all cancers and presents more frequently in men over the age of 
50 [58]. These cancers can arise anywhere in the squamous epithelium in the head and neck region, 
including oral cavity, pharynx (divided into nasopharynx, oropharynx and hypopharynx), larynx, 
paranasal sinuses/nasal cavity and salivary glands. The classical risk factors for the development 
of HNSCC are smoking, excessive alcohol consumption and HPV infection. 
HNSCC can be subdivided by HPV status; HPV-positive and HPV-negative oropharynx 
tumors take different clinical courses and have different outcomes (Table 1.1). HPV-positive 
cancer is more likely to develop in the oropharynx than anywhere else in the head and neck region, 
and it is suggested that this is due to the architecture of tonsillar crypts in the oropharynx, which 
act as a reservoir for HPV. However, there are cases of HPV+ HNSCC arising in other anatomical 
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sites within the head and neck. The palatine and lingual tonsils are the most common sites of origin 
for HPV-induced oropharyngeal cancer (OPSCC) [18, 59]. HPV-positive OPSCC patients tend to 
be diagnosed at a younger age and have fewer overall health problems than patients with HPV-
negative disease [60]. Patients with HPV-positive OPSCC have a survival advantage over those 
with HPV-negative OPSCC regardless of treatment modality [18, 61-63]. HPV-positive OPSCC 
patients tend to respond better to chemoradiation therapy [64] and have enhanced radiosensitivity 
[65]. However, patients with HPV-positive oral cavity squamous cell carcinoma (OCSCC) do not 
have the same survival advantage over HPV-negative OCSCC patients [66]; some studies suggest 
they have a worse prognosis [67]. A meta-analysis by Ragin showed no survival difference 
between HPV-positive and HPV-negative patients with cancer at non-oropharyngeal sites of the 
head and neck, including oral cavity [68].  The source of the discrepancy in outcome between the 
oropharynx and oral cavity is not entirely clear, but differences in immune response from site to  
 site may be an important factor [69]. 
The incidence of HPV-associated head and neck cancers has been increasing rapidly over 
the past few decades [70, 71]. Three out of four new oropharynx tumors are HPV-related [72]. 
This is in contrast to HPV-negative head and neck cancers, which have been declining in incidence 
primarily due to public health efforts to decrease smoking. The incidence of cervical cancer has 
also been declining due to improved screening and detection; in 2009 there were more incident 
 HPV+ HNSCC HPV- HNSCC 
Anatomic Site Oropharynx No predilection 
Age Younger Older 
Survival Improved at oropharynx,  but not other sites Poor 
Incidence Increasing Decreasing 
Risk factors Persistent HPV infection Tobacco and alcohol use 
Mutational burden Relatively low;  frequent PIK3CA mutations 
Highly mutated;  
frequent TP53, PIK3CA, 
 EGFR, NOTCH mutations 
Treatment Surgery + CRT;  de-escalation trials ongoing Surgery + CRT 
Table 1.1. Differences between HPV+ and HPV- HNSCC. 
Abbreviations:  CRT, chemoradiotherapy. 
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cases of oropharynx cancer than cervical cancer in the US [73]. Therefore, HPV+ OPSCC 
represents an increasingly concerning public health threat. Although the overall five-year survival 
rate is relatively high for HPV+ OPSCC (~80%), there is still a subset of patients who fail to 
respond to therapy or later recur for unknown reasons [74].  
Genomic landscape 
HNSCC as a whole has been studied extensively in large scale studies like The Cancer 
Genome Atlas (TCGA). TCGA mutational analysis shows frequent mutations and alterations in 
genes in critical cellular pathways including cell cycle control (TP53, CDKN2A, CCND1), tumor 
cell survival (PIK3CA, PTEN), growth signaling (EGFR), WNT signaling (FAT1, AJUBA, 
NOTCH1) and epigenetic regulation (KMT2D, NSD1) [75, 76]. However, the vast majority of 
HNSCC tumors in the TCGA are HPV-negative, which are considered a clinically distinct entity 
and have different biology than HPV-positive tumors. Only about seventy HPV-positive tumors 
are currently represented in the TCGA, and the majority of these samples are from large, 
aggressive tumors [77]. In general, these HPV+OPSCC tumors do not contain TP53 mutations and 
have a relatively low somatic mutational burden. The most frequently altered gene in HPV+ 
HNSCC is PIK3CA; many patients have activating mutations or amplifications at its locus on 3q26 
[76].  
In a small cohort of HPV+ OPSCCs, Zhang et al. reported that HPV+ HNSCCs could be 
separated into two groups with distinct gene expression signatures, one enriched for mesenchymal 
and immunological response genes (HPV-IMU) and the other enriched for keratinocyte 
differentiation genes (HPV-KRT) [78]. HPV-IMU tumors were enriched for chromosome 16q 
losses, and HPV-KRT tumors were enriched for chromosome 3q copy number alterations (CNAs) 
and activating mutations in PIK3CA. There was no significant difference in survival between the 
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two groups, but their sample size was likely not large enough to power the analysis. Due to 
underrepresentation in sequencing studies, further investigation into the somatic mutations seen in 
HPV+ samples needs to be done in order to assess potential drivers of carcinogenesis in this subset 
of patients, especially in patients with lower grade disease. 
Treatment 
 Although it has long been recognized that HPV-positive and HPV-negative HNSCC are 
distinct clinical and biological entities, the current treatment protocols mostly do not differ based 
on HPV status. Patients with advanced OPSCC, regardless of HPV status, are treated with primary 
surgery and adjuvant chemoradiotherapy (CRT) or definitive concurrent cisplatin-based CRT [79]. 
These treatments are known to cause acute side effects, including mucositis and loss of taste, as 
well as more serious long-term health problems like dysphagia, xerostomia, hearing loss, neck 
muscle fibrosis, trismus, and osteoradionecrosis of the jaw [80]. Given that HPV+ patients on 
average are younger and have longer life expectancies, these toxicities can seriously damage their 
quality of life for decades. Therefore, there has been a big push in the field to de-intensify the 
therapy for HPV+ disease with the goal of improving quality of life and reducing treatment-
induced harm while maintaining the survival rates seen with the current standard of care. Several 
clinical trials aiming to deintensify therapy for these patients have already been completed with 
many more currently underway, but the current challenge is to stratify patients into the appropriate 
risk group as the clinical and molecular markers for poor prognosis are not yet entirely understood 
[81-84]. 
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HPV Genomic Integration 
In cervical SCC 
HPV typically persists in cells as a circular episome but can also linearize and become 
integrated into the host genome. It has been of great interest to understand the implications of 
integration and to determine whether it is involved in tumor formation. HPV is commonly found 
integrated into the host genome in cervical cancer [85, 86]. Integration of HPV is characteristic of 
cervical lesion progression but may not be required for tumor formation [85, 87]. Early studies 
investigating the role of integration in cervical lesions showed that integration is a stochastic 
process or favors a preference for common fragile sites, regions of microhomology, highly 
transcriptionally active regions, or near microRNAs (miRNAs) [87-89]. There were few reported 
examples of integration into genes that led to a disruption of gene expression, and in general, 
integration was not presumed to have any major impact on gene expression. Only one study during 
this time period reported effects on gene expression; they showed integration near the cMYC locus 
on chromosome 8q24 led to overexpression of cMYC [90].  
Later studies, however, showed that integration of HPV might represent an additional 
oncogenic mechanism through direct alteration of cancer-related gene expression. One study 
showed that the majority of integration events occur in known or predicted genes or near miRNAs, 
which have major roles in regulation of cellular processes [91]. Tian et al. recently demonstrated 
frequent integration into non-coding genes known as long intergenic non-protein coding RNAs 
(lincRNAs) [92].  Hu et al. showed that integration events occur in genomic hotspot regions and 
may function to inactivate or activate genes that favor clonal expansion [89].  Bodelon and 
colleagues analyzed over 1200 integration events in cervical cancers and reported that integration 
occurred most frequently at three loci: 3q28, 8q24.21, and 13q22.1 [93]. These regions all are 
gene-rich and contain important tumor suppressors, including TP63, TPRG1, cMYC, KLF5 and 
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KLF12. They also reported that integration into genes occurs more often than expected by chance 
and may lead to functional alteration of important genes. Using an advanced technique of HPV-
capture sequencing, Holmes et al. was able to distinguish five different HPV structures in cervical 
cancers: episomal (EPI), single integration in either a colinear (2J-COL) or noncolinear (2J-NL) 
fashion associated with chromosome deletion or amplifications respectively, and multiple 
integrations either clustered in one locus (MJ-CL) or scattered at different loci (MJ-SC) [94]. In 
their cohort (n=72), they reported a relatively even distribution of each structure (29% EPI, 24% 
2J-NL, 17% MJ-CL, 16% 2J-COL, 11% MJ-SC), indicating that cervical cancers most frequently 
have at least one HPV integration site. Integration events in cervical cancer have been better 
described than in head and neck cancer, but still much is not understood about the role integration 
plays on the progression from dysplasia to invasive carcinoma.  
In HNSCC 
Like in cervical cancers, there is no consensus sequence or one location HPV integration 
is known to target in oral and oropharyngeal cancers. Integration breakpoints have been reported 
throughout the cellular genome. In HNSCC cell lines, Akagi reported that HPV insertional 
breakpoints were found at regions of genomic amplification or deletion and demonstrated an 
association of insertional breakpoints with structural variation, including chromosomal 
translocations, deletions/insertions, and rearrangements [95]. Walline investigated nine HNSCC 
cell lines and found integration in all cell lines throughout the cellular genome, eight of which had 
integration into cancer-related genes [96]. Parfenov and colleagues analyzed the genomic 
landscape of thirty-five HPV-positive HNSCCs in TCGA, including both OPSCCs and OCSCCs, 
by whole genome sequencing (WGS) and found over one hundred integration sites in 25 of the 
tumors [97]. Integration into a known gene was seen in 54% of the events and 17% integrated 
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within 20kb of a gene. Nulton et al. expanded upon this previous study to include 72 HPV-positive 
HNSCCs in the TCGA and reported that 23% of tumors showed HPV integration into the genome 
consistent with a partial deletion of E1/E2 and 44% of tumors showed episomal HPV [98]. They 
hypothesized in the remaining 33% of tumors, HPV had integrated and then was excised as a viral 
hybrid episome that can replicate autonomously.  Another recent study reported a higher frequency 
of HPV integration in HNSCC (71%) and reported structural changes in the human genome near 
the integration site in some cases but not all [99]. 
In other anogenital cancers 
HPV integration in other anogenital cancers has not been as widely studied as in cervical 
or HNSCC, and therefore it is unclear if they follow a similar mechanism for HPV-driven 
carcinogenesis. A small cohort of penile cancers was examined for HPV integration; 73% of 
samples had integrated HPV and 27% had episomal HPV [100]. Frequent HPV integration has 
also been reported in vulvar squamous cell carcinoma [101]. In 2019, Morel et al. reported the 
integration status in 93 anal squamous cell carcinomas determined by an HPV-capture sequencing 
method [102]. Similar to Holmes et al., they separated tumors into 5 categories: EPI, 2J-COL, 2J-
NL, MJ-CL, MJ-SC but the signatures they reported differed significantly. There was a much 
higher proportion of tumors with episomal HPV (45% vs 29%), and the most common form of 
integrated HPV was multiple junctions scattered across different loci (27% vs 11%). Interestingly, 
four patients showed integration into the cellular gene NFIX, and each of these patients had a 
complete response to therapy and a longer overall survival than the other patients in the study. 
HPV integration detection methods 
Whether integration of HPV is required for malignant transformation in oral/oropharyngeal 
cancers is not clear. The wide variety of techniques used to detect integration events makes it 
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challenging to compare results of different studies. Some methods try to establish the physical 
state of the virus as episomal, integrated or a mix of both within a given sample. The most 
frequently used method of this type is measuring the ratio of E2/E6 gene expression. This method 
is based on the hypothesis that during integration, the E2 gene is disrupted, leading to increased 
levels of E6. A ratio is made comparing the expression levels of the E2 and E6 genes as measured 
by quantitative reverse transcription polymerase chain reaction (qRT-PCR), assuming that a ratio 
of one means HPV is episomal and a ratio of less than one means HPV is integrated. This method 
is not as effective as others because it is based on the assumption that E2 is always disrupted and 
E6 is always increased during integration, which has been shown to not be true in all cases [89, 
97, 103]. A newer method was recently developed to distinguish the episomal state from the 
integrated state using exonuclease V, which can only digest linear DNA [104]. A sample is 
digested and then quantitative polymerase chain reaction (qPCR) is performed to the E6 region of 
HPV; if HPV is still present in the sample, that indicates HPV was not in a linear state and was 
therefore in an episome. This method is useful to characterize the physical state of HPV but gives 
no information about the location or number of HPV integration sites.  
There are many other methods used to detect and characterize HPV integration sites. The 
most commonly used methods are Detection of Integrated Papillomavirus Sequences (DIPS-PCR), 
Amplification of Papillomavirus Oncogene Transcripts (APOT), whole-genome sequencing 
(WGS), whole-exome sequencing (WES), and RNA-seq. DIPS-PCR and APOT are polymerase 
chain reaction (PCR)-based methods used to detect fusions at the DNA and RNA level 
respectively. These two methods are technically simpler and cheaper options than larger-scale 
sequencing methods like WGS or RNA-seq but may be unable to detect all integration sites and 
complicated structural changes within samples. Therefore, WGS and RNA-seq may better reflect 
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the true complexity of viral integration using tiling of paired ends across the genome, but these 
methods have limitations of their own. Due to the rare nature of integration events in the context 
of the entire genome, these methods may not have enough depth to fully characterize an integration 
site. To overcome this sensitivity problem, other groups have begun using HPV-capture 
technology before sequencing to enrich for these sites and to get deeper reads of these regions of 
interest. While this vastly improves the sensitivity, it does not help overcome the limitation of all 
next-generation sequencing methods of short-reads; these integration events are vastly 
complicated and short reads limit our ability to generate assemblies that are large enough to capture 
this complexity. Newer long-range technologies such as linked read sequencing, or PacBio and 
Nanopore long-range sequencing systems might be able to generate this type of data required to 
examine these large-scale rearrangements.   
Integration Mechanism 
The exact mechanism of HPV integration into the host genome is not known. In most 
models, both the viral and cellular genomes undergo breakage, allowing for fusion between the 
two. Some groups assert that fusion occurs as a result of cellular repair mechanisms, including 
non-homologous end joining and homologous recombination [105]. However, others have 
criticized these proposed mechanisms because small numbers of breakpoints are seen even when 
many copies of HPV are present, which argues against random breakpoints [95]. There are two 
main mechanisms that have been described: direct integration into the genome or looping 
integration (Figure 1.3). Direct integration into the host genome can result in insertion of a single 
copy or multiple concatemerized copies of HPV; in either case, both the HPV and host genomes 
undergo deletions of the flanking sequences [106]. Alternatively, Akagi developed a looping 
model for focal genomic instability to explain the genomic structural variations seen in HNSCC 
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cell lines using a chromosomal mapping technique to determine the DNA structure surrounding 
integration sites [95]. In this model, both the host and viral genomes are nicked, the viral genome 
is inserted, and a circular piece of DNA containing both is transiently formed, resulting in rolling 
circle amplification. This amplification leads to concatemer formation characterized by amplified 
segments of genomic sequence flanked by HPV segments.  This is consistent with reports from 
patient tumors with focal copy number elevation at sites of HPV integration [75, 97]. Looping 
amplification can also result in the creation of extrachromosomal HPV-human fusion episomes, 
as has been proposed by Nulton et al [98].  
Role in oncogenesis 
Integration has been thought to promote oncogenesis through the dysregulation of the 
oncoproteins E6 and E7, resulting in increased cellular proliferation and genetic instability [107]. 
Dysregulation of E6 and E7 gives the cells a selective growth advantage and allows for oncogenic 
progression. Multiple events have been described that result in dysregulation of E6/E7, including 
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Figure 1.3. Mechanisms of HPV integration. A) Two types of direct integration B) Looping integration resulting in C) Rolling
circle amplification or D) Excision of an HPV-human episome. Adapted from Groves 2018. Copyright permission received on
April 27, 2020, license number 4817180283904.
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transcripts, or (4) generation of a viral super-enhancer from repeats of regulatory elements [108].  
E2 is responsible for regulation of E6/E7, so disruption of the E2 gene or its binding sites 
allows for unregulated E6/E7 transcription. E2 can be disrupted at the genomic level or at the 
transcriptome level through integration-induced gene fracture and loss of expression of E2 itself 
or the upstream genes (E6, E7, E1). Methylation of the E2 binding sites in the URR can also lead 
to increased E6/E7 because the E2 protein is no longer able to bind and recruit cellular factors to 
repress their transcription. High levels of methylation at these sites has been reported frequently 
in HPV16+ cervical carcinomas [109, 110].  
When E1 is disrupted, lack of replicative functions can induce DNA damage and growth 
arrest, promoting focal instability at the site of integration [111]. E1 has been reported to be the 
viral gene most likely to be involved in integration breakpoints [97, 112]. In a group of cervical 
carcinomas, Brant et al. reported that the donor splicing site in E1 was recurrently involved in 
viral-cellular fusion transcripts, even when the integration junction occurred at a different position 
at the DNA level [113]. Chimeric transcripts were formed as a result of splicing between the viral 
donor site with a nearby acceptor splicing site in the human genome, resulting in disruption of E1 
and E2 expression.  
It has been shown that integration can generate hybrid E6/E7 viral-host fusion transcripts, 
which are often more stable than viral E6/E7 transcripts due to loss of viral AU-rich elements in 
the 3’ UTR [107]. Ehrig et al. cloned episomal-derived viral transcripts and a small subset of viral-
cellular fusion transcripts and compared their stability; they reported that the E6/E7 transcripts 
derived from episomal HPV were less stable than the fusion transcripts [114]. This increased 
stability may contribute to sustained higher expression of E6 and E7. 
Dooley recently showed that tandemly integrated copies of the HPV16 genome can 
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generate a super-enhancer-like element that can drive transcription of E6/E7 [115]. Super-
enhancers are clusters of traditional enhancers that are associated with the expression of 
oncogenes; binding of transcription factors and chromatin regulators like Brd4 are enriched at 
super-enhancers. Brd4 is an epigenetic regulator that recognizes acetylated lysine residues and 
recruits transcriptional complexes. This study reported that Brd4 activates viral transcription at 
these tandem integrated HPV sites, and treatment with an inhibitor of Brd4 resulted in decreased 
E6/E7 transcription and inhibited cellular proliferation.   
However, both Parfenov and Olthof reported that there are tumors with HPV integration 
that do not have increased levels of E6/E7 [97, 116]. Olthof reported that there was no significant 
difference in E2, E6 or E7 levels between integrated versus non-integrated tumors. This suggests 
that increased E6/E7 is not always the main driver of oncogenesis.   
Effect on cellular gene expression 
Integration has traditionally been thought of as promoting oncogenesis through sustained 
expression of E6 and E7. However, integration has more recently been shown to have effects on 
cellular gene expression, which may represent an additional oncogenic mechanism in the 
development of HNSCC. Parfenov saw increases in somatic DNA copy number of the integrated 
region and reported that gene disruption occurs by integration through several key mechanisms: 
tumor suppressor loss of function, enhanced oncogene expression, and rearrangements that lead to 
altered gene expression.  
Loss of function of a tumor suppressor occurs when HPV integration into a gene results in 
deletion of gene regions and generates truncated transcripts, as well as host-viral fusion transcripts. 
Parfenov reported integration into RAD51, resulting in a twenty-eight-fold amplification 
extrachromosomally, leading to alternate transcripts being generated and likely non-functional 
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RAD51 protein.  They also reported integration into ETS2, which led to deletion of exons 7 and 8. 
The overall expression of the gene was unaffected but transcription of exons 7 and 8 was 
decreased, likely leading to a truncated protein.  
HPV integration upstream of an oncogene can lead to oncogene overexpression via 
amplification of the nearby downstream region, leading to elevated transcripts. Parfenov reported 
viral integration upstream of NR4A2, leading to a 250-fold amplification of the downstream region 
and subsequent overexpression of NR4A2. NR4A2 is a transcription factor that is overexpressed 
in a wide variety of human cancers [117]. Parfenov also reported interchromosomal translocation 
of chromosomes 3 and 13, which caused overexpression of key oncogenes KLF5, TP63, and 
TPRG1. 
Walline characterized integration sites of eight HPV-positive HNSCC cell lines (seven 
HPV16 and one HPV18) by DIPS-PCR [96]. Integration into cancer-related genes was detected in 
all of the HPV16 cell lines. The HPV18 cell line, UM-SCC-105, had two integration events but 
both were intergenic. In UM-SCC-104, viral integration of HPV16 E1 into the tumor suppressor 
DCC was detected. When the transcripts of the DCC gene were interrogated, no transcripts were 
generated. This demonstrates an example of viral integration leading to disruption of a tumor 
suppressor, potentially providing a growth advantage for those cells. In UM-SCC-47, integration 
into TP63 resulted in the generation of a hybrid viral-host fusion transcript between exon 14 of 
TP63 and HPV16 E2, which resulted in a truncated DNTP63 protein as shown by Western blot. 
The other cell lines did not exhibit viral-host fusion transcripts, potentially due to integration in 
frame into introns that were subsequently spliced out.  
Akagi investigated whether the rearrangements resulting from integration generated cell-
virus fusion transcripts and altered cellular gene expression. In all ten HNSCC cell lines analyzed 
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and in one primary tumor, they found virus-host fusion transcript expression, which frequently 
confirmed the rearrangements described by WGS. They also reported multiple examples of gene 
disruption at sites of integration. In UD-SCC-2, HPV integration led to deletions and 
rearrangements of segment of DIAPH2, which resulted in viral-fusion transcripts but no native 
transcripts or functional protein. In UM-SCC-47, they reported aberrant TP63 expression due to 
HPV integration-mediated amplification, leading to viral-host transcripts and a truncated TP63 
protein. They saw additional examples of gene disruption, including amplification of the 
oncogenes FOXE1 and PIM1 in UPCI:SCC090 cells.  
Multiple groups have examined transcriptome-wide differences between integration-
positive and integration-negative tumors. Huebbers et al. showed that integration-positive tumors 
have significantly deregulated expression of genes related to epidermal development and 
differentiation, hormone regulation and processing, oxidative stress and metabolic processes 
compared to integration-negative tumors [118]. They specifically found that integration-positive 
tumors had overexpression of AKR1C1 and AKR1C3, which are members of the aldo-keto 
reductase superfamily of NADPH-dependent oxidoreductases. They further reported that HPV+ 
OPSCC patients with overexpression of these proteins had a significantly worse survival than those 
with low expression. Zhang et al. reported that HPV+ HNSCCs could be separated into two groups 
with distinct gene expression signatures, one enriched for mesenchymal and immunological 
response genes (HPV-IMU) and the other enriched for keratinocyte differentiation genes (HPV-
KRT) [78]. When they analyzed the integration status of the tumors, as assessed by viral-host 
fusion transcripts, they noted that the HPV-KRT group was enriched for samples with HPV 
integration into cellular genes, suggesting that integration can alter the expression of these cellular 
pathways. This group went on to publish an additional study directly examining the gene 
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expression signature patterns between tumors with and without viral-cellular transcripts [119]. 
Samples without fusion transcripts were enriched for genes related to the adaptive immune 
response, including lymphocyte and leukocyte activation and activity. Samples with fusion 
transcripts were enriched for genes related to ribosomal biogenesis, keratinization, and cell-cell 
adhesion. These different gene expression patterns suggest HPV integration alters the biology of 
the cells as it relates to immune response, metabolism and other critical cellular processes, the 
functional consequences of which have not been evaluated. 
However, Olthof examined patient tumors and saw no significant effect of integration on 
gene expression nor were mRNA levels of disrupted genes significantly different. Even when HPV 
was integrated directly into a gene, the mRNA expression levels were not significantly different 
from a non-disrupted gene elsewhere in the genome. Either there are other expressed gene copies 
present that allow overall expression levels to be unchanged, or viral integration did not deregulate 
genes as assessed by their method.   
Deregulation of miRNAs in HPV-positive HNSCCs could result from HPV integration 
near miRNA sites as has been shown in cervical cancer [89, 91] and HNSCC cell lines [120]. 
HPV-positive and HPV-negative HNSCCs have distinct miRNA expression patterns, and miRNA 
subsets were significantly associated with overall survival, disease-free survival, and distant 
metastasis in HPV-positive HNSCCs [121, 122]. Hui et al. reported 128 miRNAs that were 
differentially expressed between tumor and normal tissue in OPSCCs and speculated that 
integration of HPV into the genome near these miRNAs contribute to their deregulation. Wald et 
al. reported a subset of miRNAs that had altered expression in HPV16-positive HNSCC cell lines 
as compared to both HPV-negative HNSCC cell lines and immortalized normal keratinocytes 
[120]. The HPV16-positive cell lines used in this study all have been reported to contain integrated 
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HPV, suggesting a possible role of integration on the deregulation of miRNAs.  
Effect on viral gene expression 
Many studies investigating HPV integration report breakpoints throughout the viral 
genome, with an increased incidence in E1 [97, 112]. The effects of integration on viral gene 
expression are still not entirely known. Akagi reported that loss of viral segments upon integration 
or rearrangement contributes to non-uniform coverage of the viral genome when analyzed by 
RNAseq. Despite this, viral fragments containing E6 and E7 were retained and all samples had 
strong E6/E7 expression. Walline also reported enhanced E6/E7 expression upon integration, 
particularly the splice isoform E6*I, and reduced E1/E2 expression in integration-positive cell 
lines [96]. E6* transcripts are thought to be drivers of tumor development, so the expression of 
this isoform at the expense of full length E6 is significant. Despite many reports of enhanced 
oncoprotein expression, Parfenov reported that this does not occur in all integration-positive 
tumors. Although integration-negative tumors tended to have higher E2/E5 expression levels and 
lower E6/E7 than integration-positive tumors, this was not always the case.  They reported no 
correlation between the presence of integration within specific HPV genes and their expression 
level. These results further support the view that HPV plays a larger role in oncogenesis beyond 
viral oncoprotein expression and subsequent disruption of the P53 and RB axes.  
Clinical utility of integration status/site 
In cervical cancer, it was long believed that HPV integration was a required event for a 
lesion to progress from low-grade to high-grade. Tian et al. recently reported HPV integration 
frequency increases gradually through the different stages of carcinogenesis (infected but normal 
epithelium < cervical intraepithelial neoplasia (CIN) 1 < CIN2 < SCC) [92]. However, other 
studies have reported that some cervical cancers show only HPV episomes [85, 87]. Given this, it 
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has been unclear whether HPV integration, through all of its effects on both the human and viral 
genomes, has an impact on the progression of a patient’s course of disease. Many studies in both 
the cervical and head and neck literatures have attempted to assess the relationship between HPV 
integration status and patient outcomes with conflicting results depending on the methods used. 
Discovering this relationship would help determine whether HPV integration status should be 
evaluated in routine clinical practice as a predictive or prognostic factor.  
By evaluating cervical SCC tumors for integration using the E2/E6 or E2/E7 method, 
multiple groups reported that patients whose tumors contained integration had significantly worse 
outcomes than patients with only episomal HPV. Shin et al. showed in a cohort of 110 patients 
that women with episomal HPV had significantly better disease-free survival (DFS) than women 
with any integration events (integrated only and mix of integrated/episomal)[123]. Ibragimova et 
al. showed in a cohort of 140 patients that women with HPV integration had a significantly worse 
progression-free survival (PFS) and overall survival (OS) compared to women with episomal 
HPV, even when tumor stage was controlled for [124]. Women with a mix of integrated and 
episomal HPV had intermediate survival. Similarly, another group demonstrated that in women 
with stage III cervical carcinoma (n=92), those with any integrated HPV (integrated only and mix 
of integrated/episomal) vs episomal HPV had a 3X higher relative risk of a negative outcome, as 
well as worse DFS and OS [125].  
Multiple groups have also tried to assess the relationship between HPV physical state and 
outcome in HNSCC. Lim et al. used the E2/E6 ratio assay on 179 HPV+ HNSCCs to differentiate 
between tumors containing episomal, integrated or both states of HPV [126]. They reported that 
12% of the tumors contained episomal HPV only, 24% of the tumors contained integrated HPV 
only, and the remaining 64% of tumors contained both episomal and integrated HPV, but they 
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reported there was no significant difference in outcomes between these three groups. This is in 
contrast to the data reported in the cervical literature.  
Others have a used a similar principle but focused solely on the status of E2 as a marker 
for HPV physical state, as it is hypothesized E2 is disrupted/lost when HPV integration occurs. 
Two groups recently showed concordant results that patients with disrupted/lost E2 DNA and 
therefore theoretically integrated HPV had worse outcomes [127, 128]. Anayannis et al. 
demonstrated this in a small cohort of HNSCC patients (n=31) and specifically noted that these 
patients had a higher risk of locoregional failure (LRF) and lower disease-specific survival (DSS), 
and Nulton et al. used the HPV+HNSCC TCGA cohort to report that patients with integrated HPV 
have a significantly worse OS. However, Vojtechova et al. performed a similar E2 analysis on 91 
HPV+ HNSCC tumors and reported 27.5% and 72.5% of patients had integrated and episomal 
HPV respectively, but there was no significant difference in survival between these two groups 
[129]. Overall, there is some conflicting results in the literature about whether the physical state 
of the virus can be associated with patient outcome.  
There are some limitations to these prior studies; first, it has been previously established 
that not all cases of HPV integration show disruption or loss of E2, so the integration status based 
on E2/E6 ratio, E2/E7 ratio or E2 status in these studies may not be accurate and therefore tumors 
may be misidentified. These methods also do not take HPV copy number into account. Secondly, 
these studies have focused solely on the physical state of the virus (episomal vs integrated) but 
have not differentiated based on the locations of those integration sites (intergenic vs in genes/other 
genomic elements).  
In a small cohort study, our group tried to assess whether integration site location has an 
effect on patient outcome. After observing integration of HPV16 into cancer-related genes in seven 
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HNSCC cell lines, six established from patients who had progressed, our group investigated 
integration events in HPV16-positive oropharynx tumors [130]. We hypothesized that responsive 
tumors are driven primarily by viral oncoprotein expression, but recurrent tumors harbor additional 
carcinogenic events as a result of HPV integration into cancer-related genes. We expected to see 
integration into cancer-related genes leading to an alteration in gene expression and potential 
generation of fusion transcripts in tumors that later recurred but no integration or integration only 
into cellular intergenic regions in responsive tumors. The integration events in HNSCC tumors 
from 10 patients were characterized; five were responsive after therapy and five recurred after 
treatment. Our results supported our hypothesis; tumors from responsive patients had integration 
events into mainly intergenic loci and tumors from recurrent patients had integration events into 
cancer-related genes. Only one of the responsive tumors had an integration event into a gene; HPV 
L1 was found integrated into intron 4 of TP63 on chromosome 3q28. However, when transcript 
analysis of the region was performed, no fusion transcript was produced and transcripts across 
exons 4 and 5, spanning the integration site in intron 4, were produced and were in-frame. This 
suggests that TP63 may not be disrupted by this integration, or that at least one intact copy of TP63 
remains unaltered. All other responsive tumors had only intergenic integration events.  
In contrast, all five of the tumors from recurrent patients had at least one integration event 
into an intron of a cancer-related gene. There were seven total gene integration events detected in 
the five tumors, and upon transcript analysis, four of the events led to gene disruption (Figure 1.4). 
The other three events did not produce fusion transcripts and retained intact, in-frame cellular gene 
exon-exon transcripts spanning each respective intronic integration site as well as exon-exon 
transcripts downstream of the integration site. In tumor 2049 from a recurrent patient, viral 
integration into SMOC1 led to generation of a SMOC1-HPV E1 fusion transcript. The result of 
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this fusion transcript was inactivation of the gene, demonstrated by the absence of intact cellular 
exon-exon transcripts surrounding the integration site. Tumor 0843 had integration into SCN2A; 
transcript analysis revealed a complex rearrangement that produced a fusion transcript containing 
SCN2A, HPV L1, and fragments of chromosomes 2q34 and 1q32. This integration event failed to 
yield intact SCN2A exon-exon transcripts downstream of the integration site, suggesting gene 
disruption. A third tumor, 2238, had two integration events that each resulted in gene disruption. 
In this tumor, HPV L1 was integrated into NF1A and E2 integrated into SEMA6D. Neither of these 
integration events produced fusion transcripts, but disruption of both genes was evident from the 
lack of cellular exon-exon transcripts spanning the integration sites. This demonstrates that 
generation of viral/cellular fusion transcripts is not required for cellular gene disruption to occur. 
All of the tumors, including those from responsive patients, displayed strong E6/E7 gene 
expression; E6*I was the highest expressed viral gene in eight of the ten tumors [130]. This study, 
although small, aligns with the work of others that have shown HPV integration may be correlated 
with worse outcomes.  Following this study, Koneva et al. assessed integration status by searching 
for fusion transcripts within RNA-seq data from the TCGA cohort plus samples from the 
University of Michigan; they reported that patients with HPV integration had a significantly worse 
outcome that mirrored HPV-negative disease as compared to patients without HPV integration 
[119]. Taken together, these results suggest that there are multiple mechanisms leading to 
integration-mediated cellular gene disruption and that viral integration events can alter gene 
expression in the host cell. Furthermore, the consequence of these alterations in cellular gene 
expression may mediate additional carcinogenic mechanisms leading to a more aggressive tumor 
phenotype. 
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Conclusions and Thesis Aims 
There is evidence that HPV integration is implicated in oral/oropharyngeal cancer 
oncogenesis, but its exact role remains largely unknown. A variety of mechanisms of integration, 
and their effects on both the viral and cellular genome, and likely outcomes are summarized in 
Figure 1.5. Integration of HPV into the host genome may lead to increased expression of viral 
oncoproteins, and recent data suggest that viral integration contributes to alterations in host cell 
gene expression and generation of viral-host fusion transcripts. It is unclear whether integration is 
required for oncogenesis or if it is consistently associated with a more aggressive, treatment-
resistant phenotype. Our work has shown that tumors from patients with recurrent disease are more 
likely to exhibit integration into cancer-related cellular genes than those from patients who respond 
to treatment, which contain integration events primarily at intergenic sites. Therefore, the work 
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Figure 1.4: Gene disruption by integration seen in OPSCC tumors. For each event, integration is shown at DNA level and
RNA transcript level, with a postulated structure of the full integration site. A) Tumor 2049 showing integration into SMOC1 B)
Tumor 0843 showing integration into SCN2A and intergenic loci C) Tumor 2238 events 1 (integration into NFIA) and event 2
(SEMA6A).
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carried out in this dissertation aims to further investigate integration-mediated alterations of the 
cellular genome, production of viral-host fusion transcripts, and the subsequent effects that 
contribute to oncogenesis and tumor progression. Additionally, we aimed to carry out a correlative 
study on the outcome and survival of patients based on HPV integration status and site in the hopes 
of establishing the feasibility of developing viral integration evaluation as a clinically relevant 
predictive or prognostic indicator.  
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Chapter 2 HPV Genomic Integration and Survival of HNSCC Patients 
 
Abstract 
The molecular drivers of human papillomavirus-related head and neck squamous cell 
carcinoma (HPV+HNSCC) are not entirely understood. This study evaluated the relationship 
between HPV integration, expression of E6/E7, and patient outcomes in p16+ HNSCCs. HPV type 
was determined by HPV PCR-MassArray, and integration was called using Detection of Integrated 
Papillomavirus Sequences (DIPS) polymerase chain reaction (PCR). We investigated whether 
fusion transcripts were produced by reverse transcription polymerase chain reaction (RT-PCR). 
E6/E7 expression was assessed by quantitative reverse transcription polymerase chain reaction 
(qRT-PCR). We assessed if there was a relationship between integration and E6/E7 expression, 
clinical variables, or patient outcomes. Most samples demonstrated HPV integration, which 
sometimes resulted in a fusion transcript. HPV integration was positively correlated with age at 
diagnosis and E6/E7 expression. There was a significant difference in survival between patients 
with versus without integration. Contrary to previous reports, HPV integration was associated with 
improved patient survival. Therefore, HPV integration may act as a molecular marker of good 
prognosis. 
Introduction 
Human papillomavirus (HPV)-induced head and neck squamous cell carcinoma 
(HPV+HNSCC) represents a growing public health concern due to its rapidly increasing incidence 
worldwide. The incidence rate of HPV+HNSCC in the United States is 4.62 per 100,000 persons 
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[1]. This cancer type most frequently presents in the oropharynx (HPV+OPSCC) but can also arise 
in other anatomic subsites of the head and neck region [2]. HPV+HNSCC is clinically 
distinguished from HPV-negative HNSCC (HPV- HNSCC) by p16 status, which acts as a 
surrogate immunohistochemical marker for HPV positivity. Currently, HPV+ and HPV- HNSCCs 
are treated in a similar manner, but HPV+ patients have a significantly better outcome [3, 4]. 
Despite this improved outcome, still 20-30% of these patients recur or fail to respond to initial 
therapies [5]. Therefore, it is essential to understand the molecular drivers of this disease to help 
identify patients at high-risk of recurrence and to develop alternate therapy regimens.  
The process of HPV integration into the human genome is of particular interest as a 
potential driver of HPV+HNSCC. HPV has been reported to be integrated in a large proportion of 
cervical, head and neck, and other anogenital tumors with estimates ranging from ~50-70% [6-
12]. This process has been most heavily investigated in cervical cancers, but there is a growing 
body of literature implicating integration as a potentially useful biomarker in head and neck cancer. 
It has been debated whether integration is a stochastic process that occurs randomly throughout 
the genome or whether it is a targeted process. Some studies have reported that integration occurs 
into/near genes or other genomic hotspots more frequently than expected by chance and that this 
can lead to functional alteration of critical genes [6, 12, 13].  
In addition to altering cellular gene expression, integration has also been thought to 
contribute to oncogenesis by increasing HPV oncogene levels within the cell by a variety of 
mechanisms, including disruption of viral E2 [14]. E2 is frequently, but not always, disrupted as a 
result of integration, which results in increased E6/E7 due to the role of E2 as a negative 
transcriptional regulator [15]. Integration of HPV has also been reported to be associated with 
increased expression of shorter, spliced transcripts of E6 known as E6*I and E6*II [16], which 
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have been shown to be associated with dysregulation of key cancer pathways and worse outcomes 
for HPV+HNSCC patients [17]. Additionally, integration into cellular genes can lead to the 
generation of viral-host fusion transcripts, and it has been reported that these transcripts may be 
more stable than episomally-derived HPV transcripts that then allows for the HPV oncogenes to 
persist longer [18]. Some have reported that E6/E7 levels are increased in HNSCC cell lines and 
tumors with integrated HPV [19, 20], but others have reported this is not necessarily true in every 
case [12, 21]. Therefore, the relationship between HPV integration and E6/E7 levels is not entirely 
clear. 
Due to its impact on both viral and cellular gene expression, it has been of great interest 
whether integration status can be used clinically as a prognostic marker of poor outcome. A handful 
of studies have attempted to elucidate the relationship between HPV integration and patient 
outcomes with conflicting results. Some studies of integration, as measured by loss of E2, revealed 
that patients with integrated HPV had worse outcomes than those with episomal HPV [22-26], but 
others reported no significant difference between these two patient groups [27, 28]. Another group 
recently compared the survival of patients with and without viral-cellular fusion transcripts and 
found that patients with these transcripts had a significantly worse survival [29]. We recently 
examined the integration sites in patients who were responsive versus non-responsive to treatment 
and found that most responsive patients had integration into intergenic regions of the genome, 
whereas non-responsive patients had integrations into cellular genes [30]. This suggests that 
integration site may be an important factor in whether integration impacts cellular behavior leading 
to altered survival.  
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Due to this conflicting literature, we sought to clarify the relationship between E6/E7 
expression and HPV integration, as well the potential impact of integration status and site on 
patient outcomes. Here we present an analysis of HPV types, HPV integration, and oncogene 
expression in thirty-six p16+ HNSCCs (Figure 2.1). We found that HPV integrated at a similar 
frequency (60%) in our cohort as previous studies, and sometimes resulted in the generation of a 
viral-cellular fusion transcript. There was a significant positive correlation between HPV 
integration status and E6/E7 expression level, and contrary to what others have reported, we found 
that patients with tumors containing HPV integration had a significantly improved disease-specific 
survival (DSS).  
 
Materials and Methods 
Tumor Specimens: Thirty-six p16+ HNSCC tumors were obtained from the Beaumont 
Hospital BioBank (n=21, fresh frozen) and the Head and Neck Cancer SPORE Biorepository at 
















No integration/integration into 
intergenic loci
n=26
Figure 2.1. Analysis of p16+ HNSCC tumors.
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biopsies/surgical specimens for DNA analysis only. In four of these cases, frozen tissue was 
available for RNA analysis). Written informed consent to investigate their tissue was obtained 
from patients under studies approved by the Institutional Review Board at each institution. To 
reduce selection bias, p16+ HNSCC samples were acquired consecutively.  
 DNA/RNA Isolation: Tumor tissue was identified by a head and neck pathologist and was 
subsequently microdissected from 10µm sections of FFPE tissue blocks from the University of 
Michigan. Following microdissection, DNA was extracted from the tissue using the NucleoSpin 
DNA FFPE kit (Macherey-Nagel, Duren, Germany) according to the manufacturer’s protocol. 
Briefly, paraffin was dissolved with xylene, and the tissue was lysed with lysis buffer and 
Proteinase K overnight at 56° C. Following overnight digestion, DNA was de-crosslinked, loaded 
onto the NucleoSpin DNA columns, washed and then eluted in water. DNA concentration was 
measured using the QUBIT 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA).  
 RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany); RNA isolation 
was only performed from samples with fresh frozen tissue (n=20). RNA concentration was 
measured using the QUBIT 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). 
cDNA was prepared from the resulting RNA using SuperScript III (Thermo Fisher Scientific, 
Waltham, MA, USA). 
 Viral Testing: HPV PCR-MassArray was performed as previously described (Figure 2.2) 
[31]. In brief, this method detects and identifies fifteen high-risk HPV subtypes (16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73), two low-risk subtypes (6 and 11), and HPV90, 
considered to be a possible high-risk subtype. The test included interrogation of human GAPDH 
as a control for sample DNA quality and assay validity. Type-specific, multiplex, competitive PCR 
was performed to amplify the E6 region of HPV, followed by probe-specific single base extension 
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to discriminate between naturally occurring HPV present in the sample and the synthetic 
competitors included in the reaction. Matrix-assisted laser desorption/ionization time of flight 
mass spectroscopy was used for separation of products on a matrix-loaded silicon chip array. 
Samples were run in quadruplicate with appropriate positive and negative controls. 
Detection of Integrated Papillomavirus Sequences (DIPS-PCR): DIPS-PCR was 
performed to identify the sites of HPV integration in the genome of the tumors, as previously 
described (Figure 2.3) [32]. For each tumor, 0.75µg DNA was digested with one of two restriction 
enzymes, either TaqA1 or Sau3AI (New England Biolabs, Ipswich, MA, USA). Adapters 
complementary to the unique overhangs created by restriction digestion were annealed to digested 
DNA. Linear PCR was performed on each sample using multiple viral primers to amplify viral 
fragments. Following linear PCR, exponential PCR using nested viral primers and an adapter-
specific primer was performed. All DIPS-PCR primer sequences are listed in Table S2.1. Products 
Figure 2.2. HPV PCR-MassArray Method. Type-specific, multiplex, competitive PCR is performed
to amplify the E6 region of 15 hrHPV types, followed by probe-specific single base extension to
discriminate between naturally occurring HPV and synthetic competitors. These are then separated by
matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry. Figure
courtesy of Dr. Heather Walline.
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of the exponential PCR reactions were separated by gel electrophoresis (3% agarose gel). Bands 
were excised from the gel and were purified using the Qiaquick Gel Extraction Kit (Qiagen, 
Hilden, Germany). Sanger sequencing of the isolated products was performed by the University 
of Michigan Advanced Genomics Core, and the results were mapped to the human and HPV 
genomes using NCBI-BLAST.  
Integration Site Transcript Analysis: RT-PCR assays were designed to amplify 
predicted viral-cellular transcripts in cases where RNA was available and integration took place 
within a cellular gene (n=6). The designed primers are listed in Table S2.2. All successfully 
amplified transcripts were sequenced for verification.  
Viral Transcript Analysis: Samples with RNA available (n=20) were tested for HPV E6 
and E7 transcripts by both quantitative RT-PCR (qRT-PCR) and RT-PCR. qRT-PCR was 
performed using QuantiTect SYBR Green PCR kit (Qiagen, Hilden, Germany) with GAPDH as 
Figure 2.3. DIPS-PCR method. DNA is isolated and digested, potentially generating three types of DNA fragments:
human only (top), episomal HPV only (middle) or human+HPV (bottom). An adapter is ligated to the ends of each
fragment, followed by two PCR reactions with HPV-specific primers, which eliminates all human only fragments.
Products containing junctions between the human and HPV genomes are separated from episomal HPV fragments by size,
sequenced and then mapped.
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an endogenous control. Relative gene expression was calculated using the DDCt method compared 
to UM-SCC-47 (E6 and E7 expression in UM-SCC-47 were each set to 1). RT-PCR was performed 
using primers spanning the entire HPV16, HPV18 and/or HPV33 E6E7 region as appropriate; 
products were separated by gel electrophoresis (1.5% agarose gel). Primer sequences are listed in 
Table S2.3. 
Statistical Analysis: Censored Kaplan Meier curves were generated using GraphPad 
Prism 8; survival curves were compared using log-rank testing (Mantel-Cox). Associations 
between integration status and clinical variables were analyzed by Spearman’s rank correlation 
testing. P values of 0.05 or lower were considered significant.  
Results 
Clinical Summary 
Two cohorts of p16+ HNSCC patients were analyzed from either Beaumont Hospital 
(n=21) or Michigan Medicine (n=15). The patients from Beaumont Hospital were collected as part 
of a retrospective study; patients were diagnosed between 2005-2012. Patients from Michigan 
Medicine were collected prospectively and were recently diagnosed (2015 onward). Tumor 
information, patient sex, age, smoking history, year of diagnosis, treatment, and outcomes are 
summarized in Tables 2.1 and S2.4. We included thirty-four oropharyngeal SCCs, as well as one 
SCC from the oral cavity and one from the nasopharynx. As expected, there was a higher 
proportion of males included in this study (79% males, 21% females). Age at diagnosis ranged 
from 46 to 87 with an average age of 63. The majority of patients were at one time regular smokers 
(45% former smokers and 15% current smokers) with an average of 22 pack years. The remaining 
40% of patients identified as never smokers. Only a small number of patients had history of heavy  
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alcohol use (18%) defined as 8 or more drinks 
per week for females or 15 or more drinks per 
week for males; most patients identified as 
either never, light, or social drinkers.  
 Patients presented with tumors across the 
TNM classifications (AJCC 7th edition). The 
most frequently reported T classification was T2 
(36%), but there were patients with T1, T3, and 
T4 tumors as well. The majority of patients 
(71%) had some level of nodal involvement 
(26% N1, 3% N2, 23% N2b, 19% N2c). Only 
one patient had distant metastasis at diagnosis. 
The majority of patients were treated with 
chemoradiation alone or in combination with 
surgery (73%). A variety of chemotherapy 
agents were used, including erbitux, cisplatin, 
carboplatin, taxol, fluorouracil, docetaxel, and 
gemcitabine. Other treatments included surgery 
alone (12%), radiation alone (6%), and surgery 
plus radiation (6%). Patients who developed 
local recurrences or metastases were treated 
initially with chemoradiation, followed by 
Variable HNSCC Patients n=33* 
Av. Age at Diagnosis 62.9 [46-87] 
Sex  
Male 26 (79%) 
Female 7 (21%) 
Smoking Status  
Current 5 (15%) 
Former 15 (45%) 
Never 13 (40%) 
Av. Pack Years 22 [0-100] 
Drinking History  
Never 14 (42%) 
Social 5 (15%) 
Light 8 (24%) 
Heavy 6 (18%) 
Tumor Site  
Oropharynx 31 (94%) 
Oral Cavity 1 (3%) 
Nasopharynx 1 (3%) 
T Classification†  
T1 5 (15%) 
T2 12 (36%) 
T3 7 (21%) 
T4 7 (21%) 
Recurrence 2 (6%) 
Treatment  
CRT 22 (67%) 
CRT + Immunotherapy 1 (3%) 
RT 2 (6%) 
Surgery 4 (12%) 
Surgery + RT 2 (6%) 
Surgery + CRT 2 (6%) 
Disease Progression  
No LRF or DM 22 (67%) 
LRF and DM 3 (9%) 
LRF only 4 (12%) 
DM only 3 (9%) 
Unknown 1 (3%) 
Survival  
Alive, NED 21 (64%) 
Died of disease 9 (27%) 
Died, unrelated cause 3 (9%) 
Table 2.1. Clinical information summary. *Excludes 
3 patients (n=1, HPV-negative. n=2, data unavailable). 
†AJCC 7th edition.  
Abbreviations:  CRT, chemoradiation. RT, radiation 
therapy. LRF, locoregional failure. DM, distant 
metastasis. NED, no evidence of disease. 
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different chemotherapy regimens or immunotherapy.  
 We were able to collect at least two years of follow-up on the majority of this cohort with 
a median follow-up time of 3.25 years; four patients were lost to follow-up before the two-year 
mark. Only three patients (9%) developed both locoregional failure (LRF) and distant metastases 
(DM); four patients developed only LRF (12%), and three patients developed only DM (9%). Nine 
patients (27%) died of their disease; the average time to death was 1.5 years with a range of 3 
months to 3.2 years. The majority of patients who died of disease did so within 2 years of diagnosis. 
The 3-year disease-specific survival (DSS) of the OPSCC patients was 80% and did not differ 
significantly from the non-oropharyngeal patients (Figure 2.4A). We compared the survival 
curves of patients who developed LRF and/or DM versus those who didn’t, and as expected, 
patients whose tumors progressed had a significant worse DSS (Figure 2.4B). We also examined 
the influence of age, smoking and drinking histories, and T and N classification, but none of these 
variables showed significant differences in survival (Figure S2.1). 
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Figure 2.4. Kaplan Meier censored disease-specific survival (DSS) curves. A. Separated by primary tumor site (oropharynx vs non-
oropharynx) B. Separated by disease progression (patients with vs without locoregional failure (LRF) and/or distant metastases (DM), includes 
both oropharynx and non-oropharynx patients.
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Viral Genotypes 
  We tested the HPV genotypes 
present in thirty-six p16+ HNSCCs by 
HPV PCR-MassArray (Table 2.2). The 
majority of samples were positive for a 
single HPV type; thirty samples (83%) 
were HPV16+ and one sample (3%) was 
HPV18+. Four additional samples were 
positive for multiple HPV types; three samples were HPV16+ HPV33+ (8%) and one sample was 
HPV16+ HPV18+ (3%). Only one sample (3%) was negative for all HPV types and was excluded 
from further analysis. 
Viral Integration 
We tested thirty-five samples for HPV16 and/or HPV18 viral integration as appropriate by 
DIPS-PCR. We discovered at least one integration site in the majority of samples (60%) but were 
unable to find any integration sites in fourteen out of thirty-five samples (40%). Interestingly, the 
sample that was positive for both HPV16 and HPV18 (UM-3898) showed integration of both HPV 
types into different loci. Of the twenty-one samples with HPV integration, the median number of 
sites we discovered in each was 1, ranging from 1 to 4. 
By Sanger Sequencing, we were able to determine that the vast majority of cellular loci 
affected by integration were gene-poor intergenic regions of the genome; we discovered a total of 
thirty-five integration sites and only eight of them involved cellular genes (Table 2.3). However, 
given that the majority of the genome does not consist of coding genes, these findings indicate 
integration occurs into genes more often than expected by random chance. 
HPV Result No. of patients (%) by HPV type 
HPV16 30 (83%) 
HPV16 + HPV33 3 (8%) 
HPV16 + HPV18 1 (3%) 
HPV18 1 (3%) 
Negative 1 (3%) 
TOTAL 36 
Table 2.2. HPV PCR-MassArray results. 
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Of the samples with HPV 
integration, the majority had 
integration into intergenic sites 
only (n=12) (Figure 2.5). Some 
samples had integration into both 
intergenic and genic regions 
(n=6), and a few samples (n=3) 
had integration into genic 
regions only.  
A large number of 
integrations occurred in 
unplaced genomic scaffold 
regions of the genome (14/35 
events) (Figure 2.6). The most 
frequently affected chromosome 
was chromosome 13 (4/35 
events).The cellular genes 
involved in the integration sites 
we found included PTPRN2, 
SCN1B, YIPF1, SGCZ, DNAI1, 
NPAS3, UTP18, RLN1, and 
KIF21B. Integration most 
Sample ID HPV Type HPV Integration Status 
HPV/Human Region(s) 
Involved 
BMT-396 Negative - - 
BMT-8 16 N - 
BMT-56 16 N - 
BMT-280 16+33 N - 
BMT-403 16 N - 
BMT-412 16 N - 
BMT-700 16+33 N - 
BMT-1327 16 N - 
UM-3884 18 N - 
UM-3917 16 N - 
UM-3955 16 N - 
UM-3962 16 N - 
UM-3989 16 N - 
UM-4028 16 N - 
UM-4093 16 N - 





BMT-319 16 I E1: SCAF L1: Chrom 13 
BMT-322 16 I E1: SCAF 
BMT-344 16 I E1: SCAF 
BMT-400 16 I E1: SCAF 




BMT-404 16+33 I E2: Chrom 4 
BMT-411 16 I E1: SCAF 
BMT-427 16 I E1: SCAF 
UM-3940 16 I E2: Chrom 17q21 
UM-3948 16 I L1: Chrom 13q14 
UM-4067 16 I L1: Chrom 13q14 




BMT-323 16 I+G 
E1: Chrom 2q 
L2: UTP18 
L1: Chrom 4 
BMT-1159 16 I+G E1: SCAF L1: KIF21B 
UM-3898 16+18 I+G L1: Chrom 13q14 (HPV18) E1: NDST1 
UM-3938 16 I+G L2: YIPF1 L1: Chrom 6q21 
UM-3954 16 I+G E1: Chrom 3p25 L1: DNAI1-L1: NPAS3 
BMT-331 16 G E1: Chrom 1q21: SCN1B 
UM-4011 16 G E1: PTPRN2 
UM-4068 16 G L1: RLN1 
Table 2.3. Integration status and site descriptions.  
Abbreviations:  N, no sites. I, intergenic sites. G, genic sites. SCAF, genomic 
scaffold region. 
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frequently involved the HPV genes E1 (n=14) and L1 (n=11). A few integrations also involved E2 




(I) Intergenic site(s) only
(G) Genic site(s) only






























































































































































































































































































































































































































































































































































Viral-cellular Fusion Transcript Expression  
We were interested whether those integration sites involving cellular genes led to the 
generation of viral-cellular fusion transcripts that have been reported in many HNSCC samples. 
Of the nine samples with integration into a gene, RNA was available for fusion transcript analysis 
for six samples. We attempted to amplify the predicted fusion transcripts with primers designed 
spanning the junction site discovered by DIPS-PCR (Figure 2.7). In BMT-1159, we detected an 
integration of HPV16 L1 into intron 2 of KIF21B by DIPS-PCR and were able to amplify a fusion 
transcript across this junction as shown in Fig 2.7A. This amplicon was sequenced by Sanger 
sequencing to confirm its identity, and the resulting sequence matched correctly to KIF21B and 
L1. In BMT-251, HPV16 L2 integrated into intron 1 of SGCZ; we attempted to amplify junctions 
up and downstream of L2, but no amplicons were generated. We performed similar amplifications 
in BMT-323 (UTP18:HPV16 L2), UM-3954 (DNAI1:HPV16 L1:NPAS3:HPV16 L1), UM-3898 
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Figure 2.7. Fusion transcript amplification. For each integration event, the DIPS-PCR result (DNA level) is shown and the
predicted fusion transcripts (RNA level) are shown below with primer sites indicated by small gray arrows. If the fusion transcript
was successfully amplified, the gel is shown. A. BMT-1159. B. BMT-251. C. BMT-323. D. UM-3954. E. UM-3898. F. UM-4068.
(bp)
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Viral E6E7 Transcripts 
 We assessed expression of HPV E6 and E7 in samples with available RNA by qRT-PCR 
and RT-PCR (Figure 2.8). Of twenty samples tested for HPV16 by qRT-PCR, ten (50%) expressed 
E6 and E7 transcripts at varying levels relative to expression in UM-SCC-47 which very strongly 
expresses these transcripts. The remaining ten samples (50%) did not express detectable levels of 
HPV16 transcripts, despite testing HPV16+ at the DNA level. However, upon assessment of the 
expression of HPV16 E6-E7 alternate transcripts by RT-PCR, we found that five of these samples 
showed expression of one or more transcript. We found that the majority of samples expressed 
both full-length (E6FLE7) and spliced E6* transcripts (n=10), and a small number of samples 
(n=4) only expressed E6* transcripts. Samples positive for more than one HPV type (HPV16/18+ 
or HPV16/33+) were tested for transcripts of both HPV types; three samples expressed HPV16 
transcripts but not HPV18 (UM-3898) or HPV33 (BMT-700 and BMT-404) transcripts. A fourth 
sample (BMT-280) did not express HPV16 or HPV33 transcripts. There was no significant 
difference in survival between patients who expressed any E6/E7 transcripts versus those who 
didn’t, and there was also no significant difference in survival between patients who expressed 
only E6* transcripts versus both E6FL and E6* transcripts. (Figure S2.2).  
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Association with Clinical Variables 
We tested whether there was an association between HPV genomic integration and other 
variables gathered during this study by Spearman’s rank correlation (Table 2.4). We tested for a  
correlation between HPV 
integration and age, smoking 
history, drinking history, T 
classification, nodal involvement, 
E6/E7 expression level by qRT-
PCR, and expression of E6FL or 
E6*. Of these, only age (r=0.453, p=0.008), E6/E7 expression level by qRT-PCR (r=0.480, 
p=0.038) and E6FL expression (r=.459, p=0.048) demonstrated a significant positive correlation 
HPV Integration vs… Spearman’s r p value 
Age 0.453 0.008* 
Smoking 0.112 0.537 
Heavy drinking 0.219 0.220 
T classification -0.213 0.251 
Nodal involvement -0.215 0.229 
E6/E7 qRT-PCR 
expression 0.480 0.038* 
E6FLE7 expression 0.459 0.048* 
E6*-E7 expression 0.186 0.447 
Table 2.4. Correlation between HPV integration and other relevant 




























































































































































































































































































































































































































































































































































































qRT-PCR - - - - - - - - - - + + + + + + + + + +
HPV16 E6FLE7 - - - - - - - + - - + + + + + + + + + +
HPV16 E6*-E7 - - - + - - + + + + + + + + + + + + + +
HPV18 E6E7 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA -













Figure 2.8. HPV16 E6 and E7 transcript expression. A) Top: qRT-PCR primer design, Bottom: relative expression of E6 and E7, compared to UM-
SCC-47. B) Top: RT-PCR primer design to amplify alternate HPV16/18/33 transcripts, Bottom: expression of alternate transcripts. C) Summary table
of results. +, positive result. -, negative result. NA, not applicable.
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with HPV integration. This indicates that patients with integration were more likely to be older 
and had higher expression of the HPV oncogenes, specifically the full-length E6 transcript. 
We were interested in whether HPV integration influenced patient outcomes. There was 
no significant association between HPV integration and locoregional failure (p=0.676) or distant 
metastasis (p=0.659) as assessed by Fisher’s exact test, although the number of events in each 
group was likely too small to power this analysis. The DSS curves of the oropharynx patients 
separated by integration status and site are shown in Figure 2.9. Integration positive OPSCC 
patients had a significantly improved DSS compared to integration negative patients (p=0.01). 
When we separated integration positive patients by site of integration (intergenic sites only vs any 
genic sites), there was no significant difference in the survival curves. 
 
Discussion 
HPV+ HNSCC, particularly HPV+OPSCC, has been increasing in incidence rapidly over 
the past few decades [33-35]. Despite improved outcomes compared to HPV- HNSCC, still 20-
30% of patients fail to respond to initial therapies or recur [5], and the factors that contribute to 
the progression of this disease are not well understood. Given the high morbidity of HNSCC 
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NONE 13 10 4 0
p=0.052
A. B.
Figure 2.9. Kaplan Meier curves of oropharynx patients separated by integration status (A) and integration subsite (B), censored.
 54 
treatment, there is a push in the field to de-escalate treatment for patients at low risk of disease 
recurrence [36]. However, the biomarkers for response to treatment are not well developed yet, 
which makes stratifying patients difficult. Studies of treatment de-escalation are ongoing based on 
clinical risk factors [37-39], but there is still a need to investigate the molecular drivers of this 
disease in order to understand what distinguishes high versus low risk patients.  
 One such process that has been investigated as a potential driver of HPV+ HNSCC is the 
process of viral integration. Viral integration has been well characterized in cervical cancer as a 
marker of disease progression [40]. Studies in cervical cancer and HNSCC have shown that 
integration into the genome can have a variety of effects on both the cellular and viral genomes, 
including large scale rearrangements, amplifications, deletions, alterations in gene expression and 
generation of viral-cellular fusion transcripts [6-8, 11-13, 19]. Others have attempted to 
characterize the relationship between HPV integration and E6/E7 expression as well as between 
HPV integration and patient outcomes with mixed results [16, 22-31].   
Here we have presented an analysis of integration sites, HPV oncogene expression and 
associations with clinical variables in a cohort of p16+ HNSCCs. Only one patient tested negative 
for all HPV types by HPV PCR-MassArray and was excluded from further analysis. Of the thirty-
five patients tested for HPV16 and/or HPV18 integration by DIPS-PCR, we found at least one 
integration site in 60% of samples and were unable to find integration in 40%. We considered 
samples without HPV integration sites to be “integration-negative”, although it is theoretically 
possible sites of integration were missed by DIPS-PCR. However, previous studies of HPV 
integration using a variety of methods reported similar proportions, ranging from 30-50% 
integration negative [6-12]. The use of different HPV integration detection methods likely 
accounts for the variability seen between studies.  
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The use of DIPS-PCR allows us to identify the number and location of HPV integration 
sites within each sample. The majority of samples contained only one integration site, although 
there were samples in which we were able to identify more than one. Of particular interest was 
UM-3898, which contained integrations for both HPV16 and HPV18; it is unclear how integration 
of more than one HPV type might affect the progression of tumorigenesis. E1 was the HPV gene 
most frequently involved in integration (40% of sites), which is in agreement with previous studies 
[12, 41]. Even though there were a limited number of integration sites detected (n=35), we were 
able to determine that integration events took place across eleven different chromosomes 
(chromosomes 1, 2, 3, 4, 6, 7, 8, 9, 13, 14, 17). Of the integration sites detected, only eight (23%) 
were within cellular genes. Previous studies have proposed that integration is a directed process 
that occurs preferentially in/near genes or other genomic features, such as miRNAs or lncRNAs 
[6, 13, 40, 42], but our results show more of a stochastic pattern given the wide range of 
chromosomes affected and low percentage involving genes. However, the number of events we 
detected is relatively small, and therefore it is challenging to detect predilections for a specific type 
of location or chromosomal hotspots. Furthermore, the limiting size of the genomic segments in 
the SCAF insertions detected by this method prohibits precise identification of the actual locus 
affected. 
We further investigated the integration sites that occurred within cellular genes at the 
transcript level. Viral-host fusion transcripts have been reported by other groups to increase E6/E7 
expression [18-20]. Previous work from our group has shown that viral-cellular fusion transcripts 
may or may not form depending on the location of the integration site within the gene (within an 
intron vs exon) [20, 30, 43]. It is possible that some integrations within introns are spliced out and 
therefore do not produce a fusion transcript, while others may alter splice acceptor/donor sites such 
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that they are retained at the transcript level. We attempted to amplify the predicted fusion 
transcripts based on the DNA-level information we obtained from DIPS-PCR in six samples but 
were only successful in amplifying the fusion in one sample (BMT-1159). This fusion involved 
HPV16 L1 integrating into intron 2 of the cellular gene KIF21B, which encodes for a microtubule-
dependent motor protein. In this case, we were able to amplify a transcript that included KIF21B 
exon 2–KIF21B intron 2–HPV16 L1, indicating this integration resulted in alteration of splice sites 
such that intron 2 was retained in the transcript. KIF21B and other kinesin superfamily proteins 
have been implicated in the progression of many solid tumors via dysregulation of mitosis [44-
46]; therefore, it is of great interest to discover how this fusion may have played a role in the 
carcinogenesis in this case.  
We performed a similar analysis on the other five samples, three of which involved 
integration into introns and two involved gene exons, but we were unable to amplify any of the 
predicted fusion transcripts. It is not necessarily surprising that these integration sites did not yield 
fusion transcripts, but it is possible that the site is more complicated than we expect, resulting in a 
false negative. Another open question is whether these fusion transcripts are being driven off of a 
cellular or HPV promoter, which is difficult to address with the relatively short sequences obtained 
during DIPS-PCR. Gathering more sequence surrounding the site may be helpful in the future to 
amplify these transcripts.  
We also assessed expression of the E6 and E7 oncogenes within tumors with available 
RNA (n=20) by qRT-PCR, which showed varying levels of expression compared to UM-SCC-47, 
an HPV+ HNSCC cell line we showed previously has high E6/E7 expression [20]. Interestingly, 
half of the samples showed no expression of E6 or E7. However, analysis of these samples by RT-
PCR using primers designed to amplify alternate E6E7 transcripts revealed that they did in fact 
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express one or more E6E7 transcripts. It is unclear why they lacked expression by qRT-PCR, but 
it is possible they were below the threshold of detection for this assay. There were still five samples 
which showed no expression of E6E7, which is curious given that they were p16+ by IHC and 
HPV16+ at the DNA level. As a whole, the field struggles to agree on the methodology for 
determining “true” HPV positivity (p16 expression vs. HPV DNA vs. HPV RNA), as there is not 
always agreement between the methods. P16 is a useful surrogate marker, but there is an estimated 
discordance rate with HPV expression of 10-20% [47]. 
 E6/E7 are negatively regulated by E2, which is frequently reported to be disrupted by the 
process of HPV integration; therefore, some have proposed that HPV integration leads to increased 
E6/E7 levels [15]. In this cohort, we saw a significant positive correlation between HPV 
integration and E6/E7 expression levels, which supports this idea. However, it is not a perfect 
correlation; some samples with HPV integration still have no expression of E6/E7. This aligns 
with those who have published that E2 is not always disrupted during integration, and therefore 
not all integrated samples will have increased E6/E7 levels [12, 21]. Alternatively, E6/E7 
expression could be altered due to methylation of the E2 binding sites in the upstream regulatory 
region (URR) of HPV16 rather than loss of E2 itself [48, 49].  
We assessed the expression of alternate E6* transcripts; these transcripts are thought to 
contribute to a more aggressive phenotype, resulting in larger tumors and worse patient prognosis 
[17]. We found that the majority of samples expressed both E6FLE7 and alternate E6* transcripts 
with a few samples only expressing E6* transcripts. Three out of four samples that contained 
multiple HPV types only expressed HPV16 transcripts but not from other HPV types. There was 
a significant positive correlation between HPV integration and E6FL expression, but not between 
HPV integration and E6* expression. This contrasts with reports that E6* variants are more 
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common in tumors with integrated HPV [16]; however, it is possible our results differed due to 
our relatively small sample size.  
We assessed the association of HPV integration with clinical variables, including age, 
smoking and drinking histories, and T/N classification, to further examine this process. Of these, 
only age showed a significant positive correlation with HPV integration, indicating that older 
patients were more likely to have integrated HPV. It is unclear why this may be; one explanation 
could be that HPV integration occurs more frequently in older patients because DNA damage 
accumulates in aging tissue, as it has been previously proposed that HPV integration occurs at sites 
of unresolved DNA damage [50].  
We compared the survival of OPSCC patients with versus without integration and found 
that integration-positive patients had a significantly improved disease-specific survival over 
integration-negative patients. This contrasts with what others have previously reported; studies 
either reported no significant difference between the two groups or that integration-negative 
patients had a survival advantage over integration-positive patients [23-29]. It has been 
hypothesized that integration acts as an additional oncogenic driver through its various effects on 
the human and viral genomes. The reason for the discrepancy between our findings and previous 
reports is unclear, but it could be due to different methods of detecting HPV integration. These 
previous studies measured integration indirectly by assessing loss of E2 DNA [22-27] or mRNA 
[28]. Another study based integration status on the presence of fusion transcripts [29]. However, 
given that E2 is not always lost due to integration and not every integration results in a fusion 
transcript, our preferred method to detect integration is DIPS-PCR. We have used DIPS-PCR 
previously to assess integration sites in a small cohort of responsive vs non-responsive patients 
and found that non-responsive patients were more likely to have integration into genes rather than 
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intergenic loci [30]. The underlying mechanism behind the improved survival we reported here in 
integration positive patients is unclear and requires further investigation. One possible hypothesis 
is that the process of HPV integration generates tumor neoantigens which can then be recognized 
as non-self by the host immune system and enhance antitumor immune response. HPV+ OPSCC 
patients with higher levels of infiltrating CD8+ T cells, which are involved in recognizing tumor 
antigens, have been shown to have improved outcomes [51], but it is currently unknown if 
integration-positive vs integration negative patients have differential immune infiltration patterns 
and whether they can present these neoantigens for immune recognition. 
There are two major limitations of this study that could be addressed in future research. 
First, our study population was relatively small, which limited our ability to examine the 
relationships between HPV integration status/site and LRF or DM given that so few patients 
experienced these events. Secondly, we used DIPS-PCR as our preferred method of detecting 
integration sites because it is highly specific, but some of the amplicons we generated were too 
short to provide enough context for us to be able to place them at a specific locus and therefore 
had to be denoted as “genomic scaffold”. DIPS-PCR alone is also unable to distinguish between 
samples with only integrated HPV and samples that contain a mixture of integrated and episomal 
HPV, although sometimes episomal HPV copies may appear as 6-8 kb bands upon gel 
electrophoresis. It is unclear how these two samples types may differ in terms of HPV-related 
genetic or epigenetic changes. In the future, we will focus on pairing DIPS-PCR with long-range 
sequencing technologies, such as Nanopore sequencing, in order to better define the complex 
structural rearrangements caused by HPV integration [19] and explain the structural basis of local 
amplification at integration sites [12]. Comprehensive investigation of HPV integration sites and 
how they impact the course of HNSCC is necessary to provide insight for the development of 
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alternate therapies for non-responsive tumors. Overall, this study shows that HPV integration 
influences patient outcomes, which we feel warrants the implementation of viral integration 
analysis in the clinic. 
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Chapter 3 Clonality of Bilateral Tonsillar Carcinomas 
Abstract 
With oral HPV infections currently rising at epidemic rates in the western world, high-risk 
human papillomaviruses (HPV) are responsible for a significant number of oropharyngeal 
squamous cell carcinomas (OPSCC). Synchronous bilateral HPV+ tumors of both tonsils are a 
very rare event whose understanding, however, could provide important insights into virus-driven 
tumor development and progression and whether such integration events are of clonal origin. In 
this study, we analyzed three cases of bilateral tonsillar p16+ HPV+OPSCC. The viral integration 
status of the various tumor samples was determined by integration-specific polymerase chain 
reaction (PCR) methods and sequencing, which identified viral insertion sites and affected host 
genes. Analysis of the tumors revealed common HPV types and viral integration events in two 
patients, but unique HPV types and viral integration sites in another patient, providing evidence 
that multiple mechanisms may exist for the formation of bilateral tonsillar carcinomas.  
Introduction 
Persistent oral infection of HPV is a risk factor for the development of OPSCC, but the 
rates of oral infection in the general population are relatively low and clearance of infections is 
common [1-3]. It is unclear why some HPV infections are cleared while others persist, but 
smokers, males, and individuals with higher numbers of sexual partners are more likely to have a 
persistent oral HPV infection [4]. The rate of HPV-related OPSCC is rapidly increasing in the 
Western world, including the United States and parts of Europe, whereas HPV-negative OPSCC 
is declining [5, 6]. The majority of newly diagnosed OPSCCs are HPV-related malignancies [7].  
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HPV genomic integration frequently occurs in OPSCC, with estimated rates of 50-70% 
depending on the study [8-10]. Expression of HPV oncoproteins E6 and E7 is known to drive 
carcinogenesis, but recently, the genomic and transcriptomic alterations induced by HPV genomic 
integration has been investigated as an additional mechanism of carcinogenesis. It has been shown 
that genomic integration can lead to large-scale genomic rearrangements, deletions and 
amplifications that can alter expression of critical cellular genes [10, 11]. Other groups have 
reported that this process can alter gene expression transcriptome-wide, regardless of integration 
site [12, 13]. HPV integration takes place across the entire human genome with only a few reported 
hotspots, and as a whole, integration sites vary widely between samples [10, 14].  
The oropharynx encompasses the base of tongue, soft palate, posterior and lateral 
pharyngeal wall, and the tonsils. Cancer can arise in any of these anatomical subsites, but the 
lingual and palatine tonsils are by far the most common subsite for the development of 
HPV+OPSCC [15]. It is hypothesized that the thin lymphoepithelium in this region may be more 
susceptible to infection, and the architecture of the tonsil crypts act as a reservoir for HPV, leading 
to persistent infection [2]. The non-tonsillar regions of the oropharynx, however, are lined by 
stratified squamous epithelium that likely acts as a barrier to infection and thereby decreases the 
likelihood of cancer development [16]. Previous studies have compared HPV+ OPSCCs in 
tonsillar versus non-tonsillar regions and reported patients with tonsillar tumors had a better 
disease-specific survival than those with non-tonsillar tumors [17, 18]. 
 Of patients with tonsillar carcinomas, the majority of patients present with unilateral 
disease. Very few patients present with bilateral HPV+ tumors, and the literature on this 
phenomenon is somewhat limited [19-23]. A recent retrospective study reported that in a cohort 
of Danish patients, only 3.3% had synchronous bilateral tonsil cancer [24]. There are multiple 
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hypotheses on the mechanism of this event. It is possible that independent carcinomas 
spontaneously form in each tonsil as a result of HPV infection at both sites. Others however 
hypothesize the two tumors are of clonal origin, in which carcinoma develops in one tonsil and a 
clonal population migrates away from the tumor to the other tonsil (Figure 3.1). 
It has long been proposed that cancer is an evolutionary, stepwise process akin to 
Darwinian natural selection in which cells acquire new molecular alterations, resulting in a 
heterogeneous mixture of cells with differing profiles [25, 26]. Evolutionary pressure and 
competition in the tumor microenvironment allow for expansion of the fittest subclones. Subclones 
with beneficial alterations that permit them to survive the process of metastasis can then establish 
themselves as a secondary tumor in a new site. In the case of tonsillar carcinoma, it is possible that 
subclones of the original tumor break away and migrate into the other tonsil to establish a clonal 
secondary tumor. In cervical cancer, it has been reported that HPV integration may function to 
Figure 3.1. Mechanisms of bilateral tonsil tumor formation. Left: Carcinomas form
independently in each tonsil as a result of either the same HPV exposure or different HPV
exposures. Right: A tumor forms in one tonsil and then establishes a clonal tumor in the
contralateral tonsil. Adapted from Joseph 2013 [19]. Copyright permission received on April 27,
2020, license number 4817181010803.
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inactivate/activate genes that favor clonal expansion [14]. Comparison of the molecular alterations 
between the two tumors allows us to understand whether the two are related.  
Here we present three interesting cases of synchronous bilateral tonsillar p16+ 
HPV+OPSCC. In order to assess the mechanism by which these tumors arose, we performed HPV 
genotyping and integration analysis to support or dispute the clonal expansion hypothesis. We 
would expect shared HPV types and integration sites if tumors were clonally related, as it is 
unlikely two unrelated tumors would have integration into the same loci due to the stochastic 
nature of this process. Analysis of two of the tumor sets revealed identical HPV types and both 
common and unique viral integration events. This suggests a common origin but individual 
evolution of the tumors, supporting the single-clone hypothesis of bilateral tumor development. 
However, the other patient did not follow this same pattern, as their tumors contained multiple 
HPV types unique from one another with no shared HPV integration sites. This suggests either 
that their tumors were formed spontaneously or that the subclones that grew out were 
underrepresented in the original tumor and therefore could not be detected. Therefore, we have 
provided evidence that bilateral carcinomas can sometimes form as a result of clonal expansion 
from one tonsil to another. 
Materials and Methods 
Tumor Specimens: Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were 
received as described in Table 3.1. Patient one had two blocks: block 1A from a p16+ squamous 
cell carcinoma in the left tonsil and block 1B from a p16+ carcinoma in situ suspected to be a 
squamous cell carcinoma from the right side of the base of tongue. Patient two had three available 
blocks: block 2A from a p16+ squamous cell carcinoma in the left tonsil, block 2B from a p16+ 
squamous cell carcinoma in the right tonsil and block 2C from a p16+ squamous cell carcinoma 
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found in the nasopharynx. Three blocks were available from patient three: block 3A from a p16+ 
squamous cell carcinoma originating from the left tonsil, blocks 3B and 3C originating from 
different regions of a p16+ squamous cell carcinoma in the right tonsil. Slides were prepared from  
each block, and the tissues were reviewed by a head and neck pathologist.  
DNA/RNA Isolation: 10µm sections were taken from FFPE tissue blocks and mounted on 
a slide. Each section was aligned to the prepared H&E slides to identify the tumor-rich areas, and 
tissue within the tumor area was microdissected using a scalpel. Following microdissection, DNA 
and RNA were extracted from the tissue. DNA was isolated using the NucleoSpin DNA FFPE kit 
(Macherey-Nagel, Duren, Germany) according to the manufacturer’s protocol. Briefly, paraffin 
was dissolved with xylene, and the tissue was lysed with lysis buffer and Proteinase K overnight 
at 56° C. Following overnight digestion, DNA was de-crosslinked, loaded onto NucleoSpin DNA 
columns, washed and then eluted in water. DNA concentration was measured using the QUBIT 
2.0 Fluorometer.  
RNA was extracted from blocks from patient three only using the High Pure RNA Paraffin 
Kit (Roche, Basel, Switzerland) according to the manufacturer’s protocol. Briefly, paraffin was 
dissolved using heptane and methanol, and the tissue was lysed overnight at 56° C with lysis buffer 
containing Proteinase K and 10% SDS. RNA was extracted using the supplied High Pure Filters 
and wash buffers, followed by DNase I treatment. RNA was eluted in Elution Buffer and the 
concentration was measured using the QUBIT 2.0 Fluorometer.  
Patient 
# Sex Age Block A Block B Block C 
1 M 54 p16+ SCC, L tonsil p16+ CIS, R BOT - 
2 M 52 p16+ SCC, L tonsil p16+ SCC, R tonsil p16+ SCC, nasopharynx 
3 F 60 p16+ SCC, L tonsil p16+ SCC, R tonsil  p16+ SCC, R tonsil  
Table 3.1. Bilateral patient samples.  
Abbreviations: F, female. M, male. SCC, squamous cell carcinoma. CIS, carcinoma in situ. L, left. R, right. 
BOT, base of tongue. 
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p16 Staining: Tumor tissue sections were stained for p16 using the Roche/Cintec p16 
mouse monoclonal antibody (#805-4713).  
HPV Testing: HPV types present in each block were identified using HPV PCR-
MassArray as previously described [27]. In brief, this method detects and identifies 15 high-risk 
HPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73), 2 low-risk subtypes 
(6 and 11), and HPV90, considered to be a possible high-risk subtype. The test included 
interrogation of human GAPDH as a control for sample DNA quality and assay validity. Type-
specific, multiplex, competitive PCR was performed to amplify the E6 region of HPV, followed 
by probe-specific single base extension to discriminate between naturally occurring HPV present 
in the sample and the synthetic competitors included in the reaction. Matrix-assisted laser 
desorption/ionization time of flight mass spectroscopy was used for separation of products on a 
matrix-loaded silicon chip array. Samples were run in quadruplicate with appropriate positive and 
negative controls. 
Detection of Integrated Papillomavirus Sequences (DIPS-PCR): DIPS-PCR was 
performed to identify the sites of HPV integration in the genome of the tumors, as previously 
described [28]. For each tumor, 0.75µg DNA was digested with one of two restriction enzymes, 
either TaqA1 or Sau3AI (New England Biolabs, Ipswich, MA). Adapters complementary to the 
unique overhangs created by restriction digestion were annealed to digested DNA. Linear PCR 
was performed on each sample using 11 different viral primers to amplify viral fragments. 
Following linear PCR, exponential PCR using 11 nested viral primers and an adapter-specific 
primer was performed. Products of the exponential PCR reactions were separated by gel 
electrophoresis (3% agarose gel). Bands were excised from the gel and were purified by Qiaquick 
Gel Extraction Kit (Qiagen, Hilden, Germany). Sanger sequencing of the isolated products was 
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performed by the University of Michigan Sequencing Core, and the results were mapped using 
NCBI BLAST.  
Direct PCR (Patient 3 only): Additional DNA was used to amplify the viral/cellular 
regions of integration identified by DIPS-PCR. Only patient three had sufficient DNA for this 
analysis. PCR was performed with genomic DNA from each tumor sample as well as DNA from 
the DIPS linear PCR reactions in order to enrich for viral products using the primers shown in 
Table S3.1. Amplicons were separated and visualized with gel electrophoresis and were confirmed 
by Sanger Sequencing of the excised and purified bands. 
Transcript Analysis (Patient 3 only): cDNA was prepared from RNA extracted from the 
FFPE blocks. cDNA was synthesized from 1µg of RNA using Superscript III and random 
hexamers (Thermo Fisher Scientific, Waltham, MA). A no-reverse transcriptase control was 
prepared for each sample to ensure RNA purity. Primers were designed to amplify the native CD36 
and LAMA3 transcripts proximal to and downstream of each viral integration site using NCBI 
Primer-BLAST (Table S3.1). Primers were also designed to amplify across the predicted fusion 
transcripts. Reverse transcription PCR (RT-PCR) was performed using Platinum Taq DNA 
polymerase. Products of RT-PCR were separated and visualized with gel electrophoresis and were 
confirmed by Sanger Sequencing of the excised and purified bands. 
Results 
Case Reports  
Patient one: A 54-year-old male from Maastricht in the Netherlands presented with p16-
positive tonsillar carcinoma in the left tonsil and p16-positive carcinoma in situ (CIS) in the base 
of tongue.  
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Patient two: A 52-year-old male from Maastricht in the Netherlands presented with 
bilateral p16-positive OPSCC in the left and right tonsils with an additional p16-positive, Epstein-
Barr virus (EBV)-negative carcinoma in the nasopharynx.  
Patient three: A 60-year-old female nun in Cologne, Germany presented with bilateral 
p16-positive OPSCCs of the tonsils. The left tonsil was diagnosed as pT2N2bcM0, the right as 
pT2N0M0, both Grade 2. One FFPE block from the left tonsil and two FFPE blocks from biopsies 
of different regions of the right tonsillar tumor were collected. Combined radio-chemotherapy was 
recommended, but only radiotherapy was performed (59.5/50.4Gy) because the patient refused 
chemotherapy. The patient was free of disease at her last visit to the clinic two years post-diagnosis, 
after which she was lost to follow up but was reported to have died approximately one year later 
due to pneumonia. 
HPV Testing  
Staining for p16 was positive for all blocks from patients one, two and three (Figure 3.2). 
HPV PCR-MassArray determined that each block belonging to patient one contained multiple 
HPV types; block A was HPV16+ and HPV31+, while block B was HPV16+ and HPV33+ (Figure 
3.3). HPV16 was the only HPV type present in blocks A, B and C for patient two as well as patient 
three.  
Figure 3.2. Immunohistochemical staining against p16INK4a. Representative images from
patient 3 blocks A-C, V=400X.
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Integration Analysis  
 DIPS-PCR revealed multiple integration sites in the tumor samples with every sample 
containing at least one site (Table 3.2). A total of fourteen integration sites were identified; eight 
(57%) viral integrations occurred in intergenic or genomic scaffold regions, and six (43%) viral 
integrations occurred in cellular genes. Chromosome 4p15 had the most frequently affected loci. 
Breakpoints in the HPV genome were most frequently detected in E2 (36%), E1 (21%) and E5 
(21%). Breakpoints were also detected in E6, L2 and L1.  
Patient Sample Viral insertion (nt) Map Integration locus Database comparison 
1 
Left tonsil (1A) 3788 (E2) 7q22 TRRAP intron 51 NM_003496.3 
BOT (1B) 5020 (L1) 4p15 Intergenic NC_000004.12 
2 
Left tonsil (2A) 
50 (E6) Unplaced Genomic scaffold NT_187433.1 
1049 (E1) 1p22 CLCA4 exon 8 NM_012128.3 
3480 (E2) 4p15 Intergenic NC_000004.12 
Right tonsil (2B) 2139 (E1) 14q23 HIF1A exon 5 NM_001530.3 3840 (E2) 4p15 Intergenic NC_000004.12 
Nasopharynx (2C) 3840 (E2) 4p15 Intergenic NC_000004.12 
3 
Left tonsil (3A) 
2088 (E1) Unplaced Genomic scaffold NT_187433.1 
3886 (E5) 4p15 Intergenic NC_000004.12 
5617 (L2) 7q21 CD36 intron 6 NG_008192.1 
Right tonsil (3B) 3867 (E5) 18q11 LAMA3 intron 1 – intron 68 fusion NG_007853.2 
Right tonsil (3C) 3213 (E2) 4q28 Intergenic NC_000004.12 3854 (E5) 7q21 CD36 intron 5 NG_008192.1 
Table 3.2. HPV integration sites in bilateral tumor sets. 
















Figure 3.3. HPV types present in bilateral tumors. Each block represented as a
circle. Blue, block A. Green, block B. Gray, block C.
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Patient one: Each sample from patient 1 contained a unique HPV16 integration site 
(Figure 3.4a). Block 1A showed integration of E2 into intron 51 of the cellular gene TRRAP 
located on chromosome 7q22, and block 1B contained an integration of L2 into an intergenic 
region of chromosome 4q15.  
Patient two: DIPS-PCR of the tonsils and nasopharynx tumors from patient 2 revealed a 
common HPV16 E2 integration into chromosome 4p15 (Figure 3.4b). Each tonsil also contained 
additional integration sites that were not shared; the left tonsil showed integration of E6 into a 
genomic scaffold region and E1 into the cellular gene CLCA4. The right tonsil showed integration 
of E1 into exon 5 of HIF1A. 
Patient three: Multiple integration sites were detected in the tumors from patient three 
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Figure 3.4. Viral integration sites identified in each bilateral tumor. A. Patient one, B. patient 2,














































intron 6 of the cellular gene CD36. Two blocks from the right tonsil (3B and 3C) were analyzed; 
the tumor cells from the right tonsil had integrations of HPV16 E5 into intron 5 of CD36, as well 
as an additional integration of HPV16 E5 into LAMA3, which likely caused a rearrangement of 
LAMA3 intron 1 and intron 68.   
Due to an abundance of tissue, we were able to perform direct PCR to confirm the 
rearrangements and to check for gene disruption. Direct PCR and Sanger sequencing confirmed 
the LAMA3 rearrangement and integration of HPV16 E5 occurred in the right tonsil (3B), but it 
was not present in the left tonsil (3A) or the second block (3C) from the right tonsil, suggesting 
this rearrangement did not persist in the other intratumoral clonal populations (Figure 3.5a). 
Amplification of the native exons of LAMA3 DNA showed that there is an intact copy of LAMA3 
exon 2 present in all 3 samples (Figure 3.5b). However, only tumor 3B, which contained E5 
integration into LAMA3, showed an intact copy LAMA3 exon 1.  
Direct PCR of the CD36 integration site found in the right tonsil (E5-CD36 intron 5) in the 
other blocks yielded no products; similarly, direct PCR of the site found in the left tonsil (L2-
CD36 intron 6) in the right tonsil blocks yielded no products. Amplification of the native exons of 














Intron 1 Intron 68
Figure 3.5. LAMA3 and CD36 PCRs in bilateral patient 3. Red and green star indicates sample is affected by integration into
LAMA3 or CD36, respectively. PCR amplicons A. LAMA3-HPV16 E5 integration, B. Native LAMA3 exons surrounding
integration site, C. Native CD36 exons surrounding integration sites.
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Transcript Analysis (Patient 3 only) 
  RNA from the tumors of patient three revealed that HPV16 E6-E7 transcripts were present 
in each sample (Figure 3.6a). Alternate E6-E7 transcripts were visible in each sample, but not full 
length E6-E7. The left tonsil tumor 3A, and one block from the right tonsil (3B) showed expression 
of E6*I-E7 and E6*II-E7, but block 3C only expressed E6*II-E7, consistent with evolution of the 
viral segments with tumor progression. 
In order to understand whether viral integration into LAMA3 and CD36 disrupted 
expression of the genes, RT-PCR was performed. RT-PCR revealed that a transcript of the native 
LAMA3 exon downstream from the integration site (exon 2) was expressed in all 3 samples (Figure 
3.6a). Normal CD36 transcripts spanning the two integration sites (the forward primer was 
designed to amplify the cDNA junction of exon 5-6 and the reverse primer to amplify from the 
exon 6-7 junction) were also expressed in all 3 samples (Figure 3.6b). These data suggest there is 
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Exon 1 Exon 2Intron 1
Figure 3.6. Transcript expression in bilateral patient 3. Red and green stars indicate sample is
affected by integration into LAMA3 or CD36, respectively. PCR amplicons A. HPV16 E6-E7 and
CD36 exon5-6 junction to exon 6-7 junction B. Native LAMA3 exon downstream of integration site.
* * *
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normal expression of at least one copy CD36 in each tumor or that the HPV L2 and HPV E5 were 
spliced out of the transcripts along with introns 5 and 6.  
We attempted to amplify viral-host fusion transcripts that may have resulted from viral 
integration into LAMA3 or CD36. However, RT-PCR using primers designed to amplify the 
predicted fusion transcripts of LAMA3 and CD36 failed to yield any products. Every effort was 
made to limit the size of the amplicons, as FFPE RNA is usually highly fragmented making it 
difficult to amplify long products. Therefore, it is unclear whether these fusion transcripts are 
produced but unidentifiable due to fragmentation, or if they lack a viable promoter and are not 
expressed.  
Discussion 
The incidence of HPV+OPSCC is rapidly rising in the Western world. Despite an overall 
survival advantage compared to HPV-negative cancers, there is still a significant proportion of 
patients who develop local or distant recurrences within 5 years and treatment de-escalation has 
failed [29, 30]. Therefore, there is a critical need to understand the cellular and molecular 
characteristics of HPV+OPSCCs with unfavorable outcome. Some studies have shown that viral 
integration of HPV into the genome is associated with worse prognosis [12, 13, 31]  and these 
tumors have a different mutation signature, particularly of PIK3CA [32]. Viral integration into 
cellular genes may lead to disruption of gene expression and generation of viral-human fusion 
transcripts.  
Synchronous HPV+ bilateral tonsillar carcinomas are relatively rare with about 40 cases 
reported in the literature; however, studying their characteristics may contribute to our 
understanding of OPSCC [21, 24]. There is much controversy in the field whether all HPV+ 
tonsillar carcinoma patients should have their contralateral tonsil removed in order to prevent 
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missing bilateral disease [33]. Others oppose this idea due to increased morbidity of removing both 
tonsils and lack of sufficient evidence this would benefit patients, especially given that most 
patients are given adjuvant radiation and monitored closely so disease in the contralateral tonsil 
would be treated and detected [34]. The mechanism behind synchronous bilateral carcinoma 
development is debated; there is evidence for both clonal expansion of a single primary tumor as 
well as simultaneous development of independent carcinomas due to similar HPV exposure. 
Understanding how these tumors develop would help inform whether or not all patients with 
unilateral tonsillar carcinoma are at risk for development of bilateral disease. 
Here we have presented three cases of synchronous bilateral HPV+ tonsillar OPSCC. HPV 
genotyping confirmed shared HPV types in two out of three patients, whereas the remaining patient 
had discordant types. Viral integration analysis of each set of tumors highlighted a number of 
HPV16 integration sites into both intergenic and genic regions of the cellular genome. There were 
viral integrations unique to each tonsil as well as some shared sites.  
HPV analysis of the tumors from patient one revealed multiple HPV types; HPV16 was 
shared among both tumors, but other discordant types were present in each. Integration analysis of 
HPV16 in these samples revealed no shared integration sites. This suggests that these tumors could 
have formed independently, given that they contain unique HPV types and unique integration loci. 
However, it is also a possibility that these tumors came from one original tumor; a minor highly 
metastatic subclone that metastasized and dominated in the other site but could have been 
represented by too few cells and therefore too diluted in the original population to be detected by 
our assays, such that it would appear the two tumors do not share common HPV types. Further 
investigation of the genetic makeup of these two tumors would help clarify if that is the case. 
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Patients two and three, however, demonstrated clear evidence of clonally related tumors. 
All paired samples shared an HPV16 infection and demonstrated HPV16 integration into the same 
loci (chromosome 4p15 in patient two and the gene CD36 on chromosome 7q21 in patient three). 
Patient two’s shared sites were essentially identical; the same regions of HPV and chromosome 4 
were involved. In patient three however, the same cellular gene was involved, but different but 
adjacent regions (E5-L2) of HPV were involved, and the integration sites were located in two 
different but sequential CD36 introns (intron 5 and intron 6). Although the locations of integration 
are slightly different, we expect it would be unlikely to discover viral integration into the same 
gene in unrelated samples; the majority of samples have unique viral integration sites due to the 
stochastic nature of viral integration [10, 35]. There is some evidence that viral integration occurs 
preferentially into genes [14], but it is unlikely that these integrations into CD36 are the result of 
separate viral integration events in two independent tumors. Furthermore, CD36 is not reported to 
be a hotspot of HPV integration, in contrast to other genes that have been reported in several cases 
[10, 36-38]. We believe that these two tumors arose from one primary tumor with viral integration 
into CD36 that underwent clonal expansion and was subsequently established in the other tonsil. 
However, the altered site of integration also suggests the DNA was edited with tumor evolution 
over time. It is unknown whether viral integration events are stable over time or if they are subject 
to changes due to either mobile element characteristics or genomic instability. It is also possible 
that the initial CD36 integration site was established via a “looping” integration mechanism and 
some of the integrated DNA was subsequently excised during clonal expansion, as has been 
described by others [39, 40].   
In patient three, the LAMA3 gene containing the viral integration was rearranged and 
inverted as a result of HPV16 E5 insertion as shown in Figure 3.4c.  The implications of the viral 
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integration on LAMA3 function are unclear because no intact LAMA3 gene was present in blocks 
3A and 3C.  Limited analysis of the LAMA3 gene revealed that there is loss of LAMA3 exon 1 in 
the blocks without HPV E5-LAMA3 integration, but exon 2 is present in all three tumor areas.  One 
possibility to explain the observation that block 3A and 3C lost exon 1 DNA but it is retained in 
block 3B is that the initial LAMA3 integration site was established via a “looping” integration 
mechanism which reversed the orientation of the LAMA3 gene and the integrated DNA, including 
LAMA3 exon 1, was subsequently excised during clonal expansion.  This suggests that the LAMA3 
rearrangement included exon 1 and that this was an early event which was later excised as the 
tumor progressed in the right tonsil (3C) and the left tonsil (3A), but the only copy of LAMA3 
carried in those tumor cells was the copy missing exon 1. 
The cellular genes located at the HPV integration sites were of particular interest because 
of their involvement in head and neck cancer. TRRAP encodes for a protein that complexes with 
histone acetyltransferases to mediate diverse cellular processes by acetylation of histones [41]. 
Mutations in histones and histone modifiers are frequent in HNSCC, and TRRAP is amplified or 
mutated in 11% of HNSCC patients [42]. CLCA4, known as chloride channel accessory 4, has 
been shown to be an inhibitor of cellular proliferation frequently downregulated during tumor 
progression [43]. HIF1A is a well characterized marker of hypoxia that mediates cellular responses 
to hypoxic stress; HNSCC patients who overexpress HIFs have an increased risk of mortality [44]. 
LAMA3 encodes for the laminin subunit alpha-3, which is one of three members of the complex 
glycoprotein laminin 5. Laminins are components of the cellular basement membrane, and laminin 
5 is reported to be involved in cell adhesion, migration, and the differentiation of keratinocytes 
[45]. Laminin 5 has been shown to be overexpressed in invasive oral squamous cell carcinomas 
but not in premalignant lesions [46, 47]. CD36, or cluster of differentiation 36, encodes an integral 
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membrane protein involved in fatty acid import and binds many ligands including collagen, 
lipoproteins, phospholipids and long-chain fatty acids. Studies done suggest CD36 may promote 
cell migration and proliferation in oral cancers and other solid tumors [48-50]. Further 
investigation of protein expression in these samples is warranted to understand whether these 
proteins are disrupted as a result of HPV integration and whether that may have played a role in 
tumor spread.  
Our assessment of tumor clonality was limited to HPV genotype and HPV integration site, 
which other groups have also used to demonstrate tumor clonality [51, 52], but future work will 
include mutational profiling of cellular genes to strengthen our ability to assess the clonal nature 
of these samples. This work was somewhat limited by having access to only a small amount of 
FFPE tissue, resulting in a low amount of DNA and lack of quality RNA for integrated viral 
transcript analysis. This limited our ability to detect gene expression changes of regions involved 
in integration, as well as detection of the predicted viral-host fusion transcripts. It also would have 
been valuable to evaluate the metastatic lymph node associated with the left pT2N2bcM0 tonsil of 
patient 3, but DNA was not available for analysis from that metastatic lesion. Given the highly 
metastatic nature of HPV+ tonsillar carcinomas [53, 54], it is not be surprising to us that metastasis 
of HPV transformed cancer cells from one lymphoid bed within the oropharynx to another across 
the midline occurs. Overall, our study supports clonal spread from one tonsil to another, and future 
work will be focused on validating these results in other bilateral tonsil pairs.   
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Chapter 4 SearcHPV: Novel viral integration detection methodology 
Abstract 
Human papillomavirus (HPV) is a well-established driver of malignant transformation 
resulting in squamous cell carcinomas of the head and neck, uterine cervix, vulva, anus-rectum 
and penis; however, the impact of HPV integration into the host human genome on this process 
remains largely unresolved. This is due to the technical challenge of identifying HPV integration 
sites, which includes limitations of existing informatics approaches to discover viral-host 
breakpoints from short read sequencing data. To overcome this limitation, we optimized a new 
sequencing and analysis pipeline called SearcHPV. Through analysis of HPV+ models, we show 
that SearcHPV detects HPV-host integration sites with a higher confirmation rate than existing 
callers. We then performed an integrated analysis of SearcHPV-defined breakpoints with genome-
wide linked read sequencing. These methods demonstrated that HPV integration sites were found 
not only adjacent to known cancer-related genes such as TP63 and MYC, but also near regions of 
large structural variation in the tumor genome. Further, analysis of SearcHPV-assembled junction 
contigs demonstrated that the tool can be used to accurately identify viral-host junction sequences 
and showed that viral integration occurs through a variety of DNA repair mechanisms including 
non-homologous end joining, alternative end joining and microhomology mediated repair. In 
summary, we show that SearcHPV is a new optimized tool for the detection of HPV-human 




Human papillomavirus (HPV) is a well-established driver of malignant transformation in 
a number of cancers, including head and neck squamous cell carcinoma (HNSCC). Although HPV 
genomic integration is not a normal event in the lifecycle of HPV, it is frequently reported in 
HPV+HNSCC and studies have shown it may be a contributor to oncogenesis [1-4]. In cervical 
cancer, HPV integration increases in incidence during progression from stages of cervical 
intraepithelial neoplasia (CIN) I/II, CIN III and invasive cancer development [5]. This process has 
a variety of impacts on both the HPV and cellular genomes, including disruption of HPV E2, which 
acts as a transcriptional repressor of HPV E6/E7, leading to dysregulation of E6/E7 expression and 
an increase in genetic instability [6]. HPV integration occurs within or near known cellular genes 
more often than expected by chance [7] and has been reported to be associated with structural 
variations [8] and increases in DNA copy number [3]. Recent studies in HNSCCs have also 
suggested that additional oncogenic mechanisms of HPV integration may exist through direct 
effects on cancer-related gene expression and generation of hybrid viral-host fusion transcripts [9].  
A wide array of methods has been previously used for the detection of HPV integration. 
Polymerase chain reaction (PCR)-based methods, such as Detection of Integrated Papillomavirus 
Sequences PCR (DIPS-PCR) [10] and Amplification of Papillomavirus Oncogene Transcripts 
(APOT) [11], are direct ways to interrogate sites of HPV integration, but they are low sensitivity 
assays and are therefore still limited in their ability to detect the broad spectrum of genomic 
changes resulting from this process. The use of next-generation sequencing (NGS) technologies 
provides the opportunity for in-depth characterization of these events. Previous groups have 
assessed HPV integration within HNSCC tumors in The Cancer Genome Atlas (TCGA) and cell 
lines by a combination of whole-genome sequencing (WGS) and RNAseq [2, 3, 8]. To process 
WGS data, viral-human fusion callers, such as VirusFinder2 [12, 13] and VirusSeq [14], have been 
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developed. However, these strategies are designed for a broad range of virus types and require 
whole genomes to be sequenced at uniform coverage, which can result in a lower sensitivity of 
detection for specific types of rare viral integration events.  
To overcome this issue, others have begun to use HPV targeted capture sequencing, mainly 
focused on anogenital samples [5, 15-18]. This strategy allows for enrichment for integration sites 
and better coverage of regions of interest than an untargeted approach like WGS. However, 
assessing HPV integration sites from this type of data requires sensitive and accurate viral-human 
fusion detection bioinformatic tools, of which the field has been lacking. In our lab, we have found 
the previously available viral integration callers VirusFinder2 and VirusSeq, which were designed 
for WGS instead of a targeted capture approach, to have a relatively low validation rate and 
limitations on the structural information surrounding the fusion sites, which impairs the ability to 
investigate the mechanisms of integration from capture based sequencing data. Therefore, we set 
out to generate a novel pipeline specifically for targeted capture sequencing data to serve as a new 
gold standard in the field of viral integration calling. 
Materials and Methods 
Cell Line Model: UM-SCC-47 was previously derived in our lab from a surgical resection 
of a previously untreated p16+ T3N1M0 carcinoma of the lateral tongue in a 53-year-old male 
smoker [19].  The patient died within a year of diagnosis. Subsequent HPV testing demonstrated 
the cell line to be p16+ and HPV16+ [20, 21]. 
Patient Derived Xenograft (PDX) Model: Flash frozen tissue from an HPV16+ OPSCC 
PDX model (PDX-932174-294-R, subsequently abbreviated PDX-294R) was obtained from the 
National Cancer Institute Patient-Derived Models Repository (NCI-PDMR), NCI-Frederick, 
Frederick National Laboratory for Cancer Research (Frederick, MD) – https://pdmr.cancer.gov/. 
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The PDX was derived from a base of tongue squamous cell carcinoma from a 62-year-old, 
treatment naive male patient. 
DNA Isolation: High molecular weight DNA was isolated by treating the samples 
overnight at 37° with lysis buffer (10 mM Tris-HCl, 400 mM NaCl, 2 mM EDTA), 10% SDS, 
RNase A and a proteinase K solution (1 mg/mL Proteinase K, 1% SDS, 2 mM EDTA). DNA was 
then salted out of the solution with 5 M NaCl for 1 hour at 4° and precipitated with ice cold ethanol 
for 5 hours at -20°C. High molecular weight DNA was eluted in TE buffer; the quality and integrity 
of the DNA was assessed using the Tapestation Genomic DNA ScreenTape kit (Agilent, Santa 
Clara, CA). 
Targeted Capture Sequencing: DNA from UM-SCC-47 and PDX-294R were submitted 
to the University of Michigan Advanced Genomics Core for targeted capture sequencing. Targeted 
capture was performed using a custom designed probe panel with high density coverage of the 
HPV16 genome, the HPV18/33/35 L2/L1 regions, as well as over 200 HNSCC-related genes; the 
list of genes and approach for library preparation and targeted capture are detailed in Heft Neal et. 
al 2020 [22]. Following library preparation and capture, the samples were sequenced on an 
Illumina NovaSEQ6000 or HiSEQ4000, respectively, with 300nt paired end run. Data was de-
multiplexed and FastQ files were generated.  
Novel Integration Caller (SearcHPV): The pipeline of SearcHPV was illustrated in 
Figure 4.1, which overall has four main steps: (1) Alignment; (2) Genome fusion point calling; 
(3) Assembly; (4) HPV fusion point calling. These steps are elaborated in detail below. 
Alignment 
The customized reference genome used for alignment was constructed by catenating the HPV16 
genome (from Papillomavirus Episteme (PAVE) database [23, 24]) and the human genome 
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reference (1000 Genomes Reference Genome Sequence, hs37d5). We aligned paired-end reads 
from targeted capture sequencing against the customized reference genome using BWA mem 
aligner [25]. Then we performed an indel realignment by Picard Tools [26] and GATK [27]. 
Duplications were marked by Picard MarkDuplicates Tool [26] for the filtering in downstream 
steps.  
Genome Fusion Points Calling 
To identify the fusion points on the human genome, we extracted reads that have regions matched 
to HPV16 and filtered those reads to meet these criteria: (1) not secondary alignment; (2) mapping 
quality greater than or equal than to 50; (3) not duplicated. Genome fusion points were called by 
split reads (reads spanning the human genome and HPV genome) and the paired-end reads (reads 
that have one end matched to HPV and the other end matched the human genome) at the 
surrounding region (+/-300 base pairs (bp)) were used as supportive evidence to identify the fusion 
points (Figure 4.1A). The cut-off criteria for identifying the fusion points were based on empirical 
practice. We then clustered the integration sites within 100bp to avoid duplicated counting of 
integration events due to the stochastic feature of read mapping and structural variations. 
Assembly 
To construct longer sequence contigs from individual reals, we extracted supporting split reads 
and paired-end reads used for genome fusion points calling for local assembly from each 
integration event. Due to the library preparation methods we implemented for the targeted capture 
approach, some reads exhibited an insertion size less than 2 x read length, resulting in overlapping 
read segments. For such events, we first merged these reads using PEAR [28] and then combined 
them with other individual reads to perform a local assembly by CAP3 [29].  
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HPV Fusion Point Calling 
For each integration event, the assembly algorithm was able to report multiple contigs. We 
developed a procedure to evaluate and select contigs for each integration event to call HPV fusion 
point more precisely. First, we aligned the contigs against the human genome and HPV genome 
separately by BWA mem. If the contig met the following criteria, we marked it as high confidence: 
(1) Has at least 10 supportive reads 
(2) 10% < !"#$%&'	)&*+#%	,-	#%&	$,*#.+	#,	/01
)&*+#%	,-	$,*#.+
 < 95% 
Then we separated the contigs we assembled into two classes: from left side (Contig A in Fig 
4.1B) and from right side (Contig B in Fig 4.1B). For each class, if there were high confidence 
contigs in the class, we selected the contig with maximum length among them. If the class has only 
low confidence contigs, we selected the contig with most supportive reads. For each insertion 
event, we reported one contig if it only had contigs from one side and we reported two contigs if 
it had contigs from both sides (Figure 4.1C). Finally, we identified the fusion points within HPV 
based on the alignment results of the selected contigs against the HPV genome. The bam/sam file 
processing in this pipeline was done by Samtools[25] and the analysis was performed with R 3.6.1 
[30] and Python [31]. 
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Other Integration Callers: We installed and ran two other integration callers VirusSeq 
and VirusFinder2 as described below. 
VirusSeq 
We installed and ran VirusSeq following the user guide using the default parameter settings. We 
first installed the MOSAIK aligner [32]. As VirusSeq did not have a feature for users to customize 
Figure 4.1: Workflow of SearcHPV. (A) Paired-end reads from targeted capture
sequencing were aligned to a catenated human-HPV reference genome. After filtering,
fusion points were identified by split reads and paired-end reads. Informative reads were
extracted for local assembly. Read pairs that have overlaps were merged first before
assembly. Assembled contigs were aligned to HPV genome to identify the breakpoints on
HPV. (B) Contigs were divided to two classes. Contig A would be assigned to left group
and Contig B would be assigned to right group. Contig C would be randomly assigned to
left or right group. (C) Workflow for the contig selection procedures for fusion point with
multiple candidates contigs. For each fusion point, we reported at least one contig and at




































the reference genome, we indexed and used the provided built-in reference database (GIB-V [33], 
hg19 and hybrid reference genome concatenated by hg19 and 17 viral genomes). VirusSeq aligned 
the paired end reads to the catenated reference genome by MOSAIK and extracted and clustered 
split reads using a Perl script (Spanner_cross_converter.pl). Integration sites were detected by 
another Perl script (VirusSeq_Integration.pl). 
VirusFinder2 
To install VirusFinder2, we first installed all the third-party tools and Perl modules required by 
VirusFinder2. As required by VirusFinder2, we indexed the human reference genome (hs37d5) by 
Bowtie2 [34] and Blast+ [35], as well as the virus database [36] suggested by VirusFinder2 using 
Blast+. VirusFinder2 used Bowtie2 to align raw reads against the human reference genome. The 
informative reads were extracted and assembled to contigs using Trinity [37]. By mapping contigs 
to the virus reference database, VirusFinder2 detected the virus and identified the virus type. It 
then applied the VERSE algorithm to customize the reference genome. 
Sanger Sequencing: Primer sets (n=46) were designed to amplify across the predicted 
HPV-human junctions from the contigs generated by the integration callers (Table S4.1). Primers 
were designed using NCBI Primer-BLAST. PCR was performed using each of the 46 primer sets 
multiplexed with GAPDH control primers using 50 ng DNA and Platinum Taq (Thermo Fisher 
Scientific, Waltham, MA) following the manufacturer’s instructions. The PCR products were run 
by gel electrophoresis on a 1.5% agarose gel, followed by isolation of DNA from the bands at the 
predicted molecular weights using the Qiaquick Gel Extraction Kit (Qiagen, Hilden, Germany). 
These products were sent for Sanger sequencing at Eurofins Genomics (Louisville, KY) and 
mapped back to the predicted sequence to confirm sequence identity. 
 91 
Characterization of Integration Calls: Circos plots detailing integration sites were 
generated using the Circlize package [38] in R 3.6.1 [30]. Distance of each integration site from 
genes was calculated based on NCBI RefSeq genes (Release 105.20190906). Microsatellite repeats 
(2-6 bp in length, minimum of 3 repeats) were detected using the Tandem Repeats Finder 
(http://insilico.ehu.es/mini_tools/microsatellites/?info) [39].  
10X Linked Reads Sequencing: High-molecular weight DNA from UM-SCC-47 and 
PDX-294R was submitted to the University of Michigan Advanced Genomics Core for 10x-based 
linked read library generation and sequencing on an Illumina NovaSeq6000 with 300nt paired end 
run. Samples were de-multiplexed and FastQ files with matched index files were generated using 
Long Ranger Version 2.2.2. Data was visualized using the Loupe software package, Version2.1.1 
(2.4). Structural variation calls were considered high confidence if they occurred in unambiguous 
regions of the reference genome and there were 3 or more supporting sequencing barcodes detected 
at the site. The raw data was deposited to the sequencing read archives under identification number: 
PRJNA668771.  
Results 
SearcHPV pipeline  
Viral integration has traditionally been detected using whole genome sequencing data, but 
these events are relatively rare in the genome, so a targeted approach is helpful to enrich for these 
events to improve coverage of these regions. HPV targeted capture sequencing allows for deeper 
investigation of these events, but the current bioinformatics pipelines available are not designed 
for this type of data. Given the limitations with previous sequencing approaches and their 
associated viral integration callers, we set out to design a new targeted sequencing-based pipeline 
to improve HPV integration calling in HNSCC samples. A schematic of our pipeline which we 
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termed “SearcHPV” is shown in Figure 4.1. Two HPV16+ HNSCC models, UM-SCC-47 and 
PDX-294R, were subjected to targeted-capture based Illumina sequencing using a custom panel 
of probes spanning the entire HPV16 genome, L1 and L2 of HPV18/33/35, and over two hundred 
human genes known to be frequently altered in HNSCC. The paired end reads for each sample 
then went through the four steps of analysis of SearcHPV: alignment to custom reference genome, 
genome fusion points calling, local assembly and precise fusion point calling. Analysis of the 
integration sites in the cell line and PDX models using our pipeline SearcHPV showed a high 
frequency of HPV16 integration with a total of six events in UM-SCC-47 and sixty-nine unique 
events in PDX-294R (Figure 4.2, Table S4.2-S4.3).  
Comparison to other integration callers and confirmation of integration sites  
In addition to using SearcHPV, we assessed UM-SCC-47 and PDX-294R for HPV 
integration events using two previously established integration callers, VirusFinder2 and VirusSeq 
(Figure 4.3). We found that SearcHPV called HPV integration at a much higher rate than either 
previous caller. There were a large number of sites that were only identified by SearcHPV (n=49), 
although there were also sites that were identified by two or more callers (n=26). VirusFinder2 
and VirusSeq also had a number of sites (n=20 and n=8, respectively) that were not detected by 
Figure 4.2: Distribution of breakpoints in the human and HPV genomes called by SearcHPV. Links of breakpoints in the
human and HPV16 genomes for (A) UM-SCC-47 and (B) PDX-294R.
A. B.
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our pipeline. In order to assess the accuracy of each caller, we performed PCR on source genomic 
DNA followed by Sanger sequencing with primers spanning the HPV-human junction sites 
predicted by either SearcHPV, VirusFinder2 and/or VirusSeq (Figure S4.1). We were able to test 
a total of forty-six integration sites using this method, twenty-five of which were unique to 
SearcHPV and eight which were unique to VirusSeq. VirusFinder2 does not allow for local 
assembly of the integration junctions which rendered us unable to test sites that were unique to 
this program. SearcHPV had an overall confirmation rate of 27/38 (71%), with the confirmation 
rate for sites unique to SearchHPV showing slightly higher (18/25 (72%)). In contrast, the overall 
confirmation rate for VirusSeq was 7/14 (50%), with only a 2/8 (25%) success rate for sites unique 
to VirusSeq. The sites that were identified by all three integration callers had the highest 
confirmation rate (4/4 (100%)). The confirmation rate of high confidence SearcHPV sites was 

























A. Integration Calls Integration Confirmation Rates
Figure 4.3: Comparison of integration sites called by SearcHPV, VirusSeq and VirusFinder2. (A) Number of
integration sites called by each program. (B) PCR confirmation rate of sites called by each program.
 94 
Localization of integration sites  
We next examined the integration sites detected in the HNSCC models by SearcHPV. We 
identified a large number of integration events, with six called in UM-SCC-47 and sixty-nine 
unique HPV integration sites called in PDX-294R (Figure 4.4).  
The six integration sites discovered in UM-SCC-47 were clustered on chromosome 3q28 
within/near the cellular gene TP63 and either involved the HPV16 genes E1, E2 or L1. Three 
integration sites were called within intron 10 of TP63, and there was one integration each in intron 
12 and exon 14. One integration site was 8.6 kilobases (kb) downstream of the TP63 coding region.  
Within PDX-294R, HPV16 integration sites were identified across 18 different 
chromosomes (chromosomes 1-15, 17-19), occurring most frequently on chromosome 3. The most 
frequently involved HPV genes were E1 (21/ 69 (31%)) and L1 (18/69 (26%)). Most of the 
integration sites discovered in this sample mapped to within/near (<50 kb) a known cellular gene 
(45/69 (66%)). Of the sites that fell within a gene, the majority of integrations took place within 
an intronic region (35/41 (85%)) with only a small number of events occurring within a gene 






































































saw some examples of loci that contained multiple integration sites closely clustered around 
cancer-relevant genes, including ZNF148 and SNX4 on chromosome 3q21.2, MYC on chromosome 
8q24.21 and FOXN2 on chromosome 2p16.3. 
Association of integration sites and large-scale duplications 
We predicted that the complex integration sites we discovered in UM-SCC-47 and PDX-
294R would be associated with large-scale structural alterations of the genome, such as 
rearrangements, deletions and duplications. To identify these alterations, we subjected UM-SCC-
47 and PDX-294R to 10X linked-read sequencing. We generated over 1 billion reads for each 
sample (Table S4.4), with phase blocks (contiguous stretches of DNA from the same allele) of up 
to 28.9M and 3.8M bases in length for UM-SCC-47 and PDX-294R, respectively (Figure S4.2). 
This led to the identification of 444 high confidence large structural events in UM-SCC-47 and 
126 events in the PDX-294R model. Upon performing integrated analysis with our SearcHPV 
results, a 130 kb duplication surrounding the integration events in TP63 in UM-SCC-47 was 
discovered (Figure 4.5A). Similarly, in PDX-294R, 32/69 (46%) integration sites were within a 
region that contained a large-scale duplication, while the other 37 integration events fell outside 
regions of large structural variation. This suggested that in this PDX model, 32/126 (25%) large 
structural events were potentially induced during HPV integration. For example, the clusters of 
integration events surrounding ZNF148 and SNX4, MYC, as well as FOXN2 were all associated 
with large genomic duplications in PDX-294R (Figure 4.5B-D).  
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Descriptive analysis at junction sites 
Finally, we were interested to see whether the junction sites called in UM-SCC-47 and 
PDX-294R by SearcHPV followed any patterns in terms of 1) direction of the HPV genome in 
relation to the host genome, 2) the presence of microsatellite repeats and 3) microhomology 












x3 x2 x7 x2
Figure 4.5: Genomic duplications associated with HPV integration in UM-SCC-47 (A) and
PDX-294R (B-D). Red arrows indicate integration site. Each plot shows the number of
overlapping barcodes observed in sequencing reads of that region.
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stochastic; HPV read in the same and opposite direction as the human genome at approximately 
equal rates (49% and 51%, respectively). HPV integration into microsatellite repeats within the 
human genome was a relatively rare event and only occurred in a few cases (6/69 (8%)).  
To evaluate microhomology, we examined the degree of sequence overlap at the junction 
site. We saw three types of junction points: those with a gap of unmapped sequence between the 
human and HPV genomes, those that had a clean breakpoint between the genomes, and those with 
sequence that could be mapped to both the human and HPV16 genomes (Figure 4.6A). The 
majority of sites in both samples had at least some degree of microhomology (56%) (Figure 4.6B-
C). Integration sites with clean breaks (0 bp overlap) and 3 bp of overlap were the most frequently 
seen junctions in PDX-294R, but there was a wide range of levels seen, going up to 17 bp of 
overlap. There was also a large number of junctions with gaps between the human and HPV 
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Figure 4.6: Microhomology at junction points. (A) The three types of junction points. (B) Level of microhomology




To interrogate HPV integration sites through targeted capture sequencing data, we 
developed a novel bioinformatics pipeline that we termed “SearcHPV” and preliminarily show 
that it operated in a more accurate and efficient manner than existing pipelines. The software also 
has the advantage of performing local contig assembly around the junction sites, which simplifies 
downstream confirmation experiments. We used our new caller to interrogate the integration sites 
found in two HNSCC models in order to compare the accuracy of our caller to the existing 
pipelines. We then evaluated the genomic effects of these integrations on a larger scale by 10X 
linked-reads sequencing and performed an integrated analysis of the capture-based and whole 
genome data sets to identify the role of HPV integration in driving structural variation in the tumor 
genome.  
 Using SearcHPV, we were able to investigate the HPV-human integration events present 
in UM-SCC-47 and PDX-294R. Importantly, UM-SCC-47 has been previously assessed for HPV 
integration by our group and others using a variety of methods [8, 20, 21, 40, 41], which we 
leveraged as ground truth knowledge to validate our integration caller. All previous studies were 
in agreement that HPV16 is integrated specifically within the cellular gene TP63, although the 
exact number of sites and locations within the gene varied by study. In this study, SearcHPV also 
called HPV integration sites within TP63. We found integrations of E1, E2 and L1 within TP63 
intron 10, L1 within intron 12 and E2 within TP63 exon 14. These integration sites were also 
detected using DIPS-PCR [21] and/or WGS [8] with the exception of E1 into intron 10, which was 
unique to our caller and confirmed by direct PCR followed by Sanger sequencing. It is possible 
that the integration sites detected in this sample represent multiple fragments of one larger 
integration site. There were additional sites called by other WGS studies that we did not detect 
(intron 9 [8] and exon 7 [20]), although it is possible that alternate clonal populations grew out due 
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to different selective pressures in different laboratories. Nonetheless, the analysis clearly 
demonstrated that SearcHPV was able to detect a well-established HPV insertion site. 
In contrast to UM-SCC-47, to our knowledge, PDX-294R has not been previously analyzed 
for viral-host integration sites and therefore represented a true discovery case in our study. We 
identified widespread HPV integration sites throughout the host human genome and also observed 
that 66% of integration sites were found within or near genes (<50 kb). This aligns with previous 
reports that integrations are detected in host genes more frequently than expected by chance [2, 3, 
7, 42]. Further, we identified several integration events at or near previously established cancer-
related genes, including MYC. Importantly, MYC has also been identified as a potential hotspot for 
HPV integration [7, 43] and the junctions we detected in/near this gene had 2-4 bp of homology, 
potentially driving this observation. Accordingly, an HPV-integration related promoter duplication 
event, which may be expected to drive expression, would be consistent with a novel genetic 
mechanism to drive expression of this oncogene.  
TP63 has also been reported to be a hotspot for HPV integration, as it has been recorded in 
multiple samples besides UM-SCC-47 [3, 7, 44, 45]. There is a high degree of microhomology 
between HPV16 and this gene [44], and the junctions we found within TP63 mostly had 1-3 bp of 
microhomology, again serving as a possible mechanism for frequent integration here. Given the 
high frequency of molecular alterations in the epidermal differentiation pathway (e.g. NOTCH1/2, 
TP63 and ZNF750) in HPV+ HNSCCs, this data supports HPV integration as a pivotal mechanism 
of viral-driven oncogenesis in this model [46].  
 HPV integration sites have been associated with structural variations in the human genome 
and have been found at regions of amplification or deletion [3, 8, 46], which may support the 
selective advantage of integration into/adjacent to host cancer-related genes. This structural 
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variation event is thought to be due to the rolling circle amplification that takes place at the 
integration breakpoint, leading to the formation of amplified segments of genomic sequence 
flanked by HPV segments [8, 47]. These structural alterations are frequently associated with 
changes in gene expression [3]. Our data are consistent with these previous reports in that 
approximately half of the integration events we discovered were associated with a large-scale 
amplification. Accordingly, in UM-SCC-47, the integration sites within TP63 were also associated 
with a large-scale amplification. It is unclear why some integration sites were associated with 
structural variants and others were not, but it is possible that at some points in the genome, HPV 
integrated by an alternative mechanism to rolling circle amplification as has been previously 
described [47]. It is also unclear how these large amplifications may affect gene expression in 
these samples, as we did not evaluate this in the current study. 
Importantly, this observation that HPV integration events tended to be enriched in cellular 
genes could be due to multiple different mechanisms. Integration could occur preferentially in 
regions of open chromatin during cell replication and keratinocyte differentiation. Other potential 
mechanisms are: 1) that HPV integration is directed to specific host genes by homology or 2) that 
HPV integration is random, but events that are advantageous for oncogenesis are clonally selected 
and expanded, and we would postulate that the later mechanism may be enriched for non-
homology based DNA repair mechanisms. Therefore, to help resolve differences in the mechanism 
of integration, we assessed microhomology at the HPV-human junction points. Early in the HPV 
literature, it was described that HPV integration may be targeted to chromosomal fragile sites 
where DNA double strand breaks are unrepaired [42, 48, 49], but  it is still unclear at this point 
how DNA damage repair pathways play a role in resolving these breakpoints. We saw that the 
majority of breakpoints had at least some level of microhomology, ranging from 1-17 bp of 
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overlap. The most frequent levels of overlap were 0 and 3 bp, which potentially implicates non-
homologous end joining (NHEJ) in repair at these sites, since this pathway most frequently results 
in 0-5 bp of overlap [50]. There were also a number of junction sites that demonstrated a gap of 
inserted sequence between the HPV and human genomes. It has been described that during 
polymerase theta-mediated end joining (TMEJ), stretches of 3-30 bp are frequently inserted at the 
site of repair, possibly accounting for the sites we saw with a gap between genomes [51]. However, 
given the relatively small number of events we examined, we expect that future analysis with our 
pipeline will be able to help resolve the specific role of each DNA repair pathway in HPV-human 
fusion breakpoints. 
Overall, our new HPV detection pipeline SearcHPV overcomes a gap in the field of viral-
host integration analysis. We recognize that the performance of SearcHPV has only been examined 
on two HPV+ HNSCC models, and we were only able to compare its sensitivity and accuracy to 
other programs based on a relatively small number of overall events. Therefore, we are unable to 
determine statistical significance differences in the accuracy and sensitivity of our caller. However, 
based on our preliminary findings, we demonstrated a trend that our caller was more accurate. In 
the future, cohort-based studies of HPV+ HNSCC samples with similarly rigorous validation will 
further our understanding of the sensitivity of the software. Most importantly, we expect that the 
application of this pipeline in large HPV+ cancer tissue cohorts will also help advance our 
understanding of the potential oncogenic mechanisms associated with viral integration-based 
oncogenesis. Indeed, with the emerging set of tools such as SearcHPV that are rapidly becoming 
available for different types of next generation sequencing data, we believe the field is now primed 
to make major advances in the understanding of HPV-driven pathogenesis, some of which may 
lead to the development of novel biomarkers and/or treatment paradigms.  
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Chapter 5 Discussion  
Summary  
 Human papillomaviruses (HPV) are implicated in the development of a number of cancers, 
including head and neck squamous cell carcinomas (HNSCC), particularly of the oropharynx 
(OPSCC). One particular process that has been recently investigated as a potential driver of HPV-
related cancers is viral integration into the human host genome, as this is frequently observed in 
tumors but is not required for the lifecycle of this DNA virus [1-6]. In Chapter 1, we explored the 
reported mechanisms of this process and how it affects the HPV/human genomes and 
transcriptomes. The leading model of HPV integration to explain the genomic instability 
associated with this process is described as looping amplification that results the formation of 
concatemers consisting of amplified segments of human sequence flanked by HPV segments [7]. 
This rolling circle amplification results in disruption of viral regulatory regions, such as E2 and 
E1. This potentially results in overexpression of the viral oncogenes E6 and E7, specifically 
alternate transcripts of E6 known as E6* that are associated with a more aggressive phenotype [8-
11]. It can also result in disruption of adjacent host genes and lead to large scale structural variants, 
including deletions, amplifications and rearrangements [5, 7]. These genome-level changes can 
then impact the tumor transcriptome; gene expression differences have been reported for genes 
affected directly by integration, but transcriptome-wide changes have also been reported [5, 7, 11, 
12]. Despite all that has been reported about HPV integration, how exactly this process drives 
oncogenesis of HPV+ OPSCCs is still unclear. 
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Our group has previously assessed HPV integration sites in patient specimens but only in 
a limited cohort of ten patients [13]. Therefore, in Chapter 2, we aimed to examine these events 
in a larger set of patients (n=36) in order to investigate the relationship between HPV integration 
and 1) HPV oncogene expression and 2) clinical outcome. Previous work investigating the 
relationship between HPV integration and HPV oncogene expression has shown conflicting 
results. It has long been thought that the process of HPV integration leads to an increase in HPV 
E6/E7 expression due to the loss of the transcriptional repressor E2 [8]. This unregulated 
expression of E6/E7 can lead to increased proliferation and genomic instability due to their 
interaction with cell cycle control proteins TP53 and RB, respectively [14, 15]. However, others 
have reported that not all tumors with HPV integration showed increased expression of E6 and E7 
[5, 16].  
In our cohort of thirty-six patients, we assessed HPV integration status by Detection of 
Integrated Papillomavirus Sequences polymerase chain reaction (DIPS-PCR) and expression of 
the HPV oncogenes E6 and E7 by both quantitative and non-quantitative reverse transcription 
polymerase chain reaction (qRT-PCR and RT-PCR) to show expression of E6* variants. Our 
results demonstrated a high frequency of HPV integration similar to that of other reports (60% of 
samples). We saw a significant positive correlation between HPV integration and E6E7 expression 
level as measured by qRT-PCR. When we looked at the association between integration and the 
expression of either E6FL-E7 or E6*-E7 transcripts, integration was only significantly associated 
with the expression of E6FLE7 transcripts. This indicated to us that in most cases HPV integration 
does lead to increased E6/E7 expression, which likely contributes to increased genomic instability. 
However, there was no difference in survival between patients with high versus low expression of 
E6E7 in our cohort.  
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In the study of these thirty-six patients, we also aimed to investigate the relationship 
between HPV integration and clinical outcome, specifically disease-specific survival (DSS). A 
handful of previous studies have tried to assess whether patients with HPV integration have a 
worse outcome, mainly measuring integration status by E2 loss, although one group used the 
presence or absence of viral-cellular fusion transcripts to distinguish between integration positive 
versus negative [17-20]. One group reported no significant difference in survival between the two 
groups [20], but others reported that integration-positive patients as assessed by viral-host fusion 
transcripts had a significantly worse outcome, suggesting that this process may act as an additional 
mechanism of carcinogenesis.  
When we examined integration-positive versus integration-negative patients in our cohort, 
our results actually showed the opposite; integration positive patients had a significantly improved 
DSS. We also tried to separate integration-positive patients into two subcategories, those with 
integration into gene-poor regions of the genome and those with integration into genes, given that 
integration into genes may impact the tumor transcriptome. In our cohort, there was no significant 
difference in survival between these groups, likely due to small sample sizes. The reason for the 
discrepancy in results between studies is not entirely clear, but the method for integration detection 
likely contributes to this issue. One possible hypothesis to explain our results is that the high levels 
of genomic instability due to HPV integration somehow leads to a better response to therapy in 
patients, potentially through an improved immune response.  
In Chapter 3, we leveraged the stochastic nature of HPV integration to investigate the 
clonality of bilateral tonsillar carcinomas. These rare tumors only occur in about 3% of OPSCC 
patients, but the mechanism behind their formation is of great clinical interest [21, 22]. When a 
patient presents with HPV+ tumors in both tonsils, it is unclear whether those tumors formed 
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independently due to exposure to one or more HPV types or if there was one original tumor that 
migrated across the midline into the other tonsil. There have been reports that support both 
mechanisms, but in general, this is an understudied process [23-25]. It would not be entirely 
surprising for a clonal population to establish a secondary tumor given the highly metastatic nature 
of HPV+ OPSCC which frequently is observed in the surrounding lymph nodes [26, 27]. However, 
there is not currently a good understanding of how that may occur. Investigation of these tumors 
also provides the opportunity to think more broadly about how and why HPV integrations may 
contribute to the fitness of cancer cell clones. 
In order to investigate the clonality of bilateral tonsillar carcinomas, we assessed the HPV 
genotypes and HPV integration sites found within three pairs of tumors. We would expect clonal 
tumors to share HPV genotypes and HPV integration sites. Given that HPV integration rarely 
occurs in the same locus from sample to sample, we would expect that unrelated tumors would not 
share integration sites. In two out of three patients (Patients 2 and 3), HPV16 was the only HPV 
type present in each tumor. In the remaining patient (Patient 1), both tumors shared an HPV16 
infection, but they also had an additional discordant HPV type (HPV31 and HPV33). When the 
HPV16 integration events were assessed by DIPS-PCR in all samples, nearly identical HPV 
integration sites were detected between the tumor pairs in Patients 2 and 3, but Patient 1 had only 
discordant HPV integration sites. The tumor pairs from Patient 2 showed HPV16 E2 integration 
into the exact same intergenic locus on chromosome 4p15. The tumor pairs from Patient 3 showed 
integration into the same cellular gene, CD36, but the HPV gene and exact site within CD36 
differed slightly.  
These data suggest that Patient 1’s tumors were likely independently formed, given the 
discordant HPV types and integration sites. However, it is also possible that these tumors were in 
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fact clonally derived, but the establishing clone was so diluted that it could not be detected. Further 
investigation of the genetic alterations in these tumors would be necessary to differentiate between 
these two hypotheses. Based on the shared HPV types and HPV integration sites seen within the 
tumor pairs of Patients 2 and 3, we concluded these tumors were likely of clonal origin. The 
integration site in Patient 3 was not identical, but CD36 is not a known integration hotspot, so it is 
unlikely to see integration here in unrelated samples. However, the altered site of integration also 
suggests the HPV-containing DNA was edited with tumor evolution over time. It is unknown 
whether viral integration events are stable over time or if they are subject to changes due to either 
mobile element characteristics or genomic instability. The observation that clonal populations of 
cells in different anatomic sites with the same integration sites are preserved also implies that these 
are beneficial fusions that somehow give the cells a survival advantage, but how exactly these 
fusions contribute to cancer cell fitness is still unclear. 
In Chapter 4, we explored a new methodology to detect HPV integration and leveraged 
this novel sequencing pipeline to explore in depth the viral-host fusions in two HPV+HNSCC 
models. We have mainly used DIPS-PCR to detect HPV integration [10, 13, 28, 29]; however, 
there are limitations to this method. Due to its time-consuming and labor-intensive protocol, it 
cannot be easily scaled up to assess a high volume of samples. Next-generation sequencing (NGS) 
overcomes this issue and has the capability to rapidly process a large number of samples. Whole 
genome sequencing has been used on HPV+ cell lines and a relatively large panel of HPV+ 
HNSCCs in The Cancer Genome Atlas (TCGA), as has RNAseq [4, 5, 7]. However, the rare nature 
of HPV integration sites makes it challenging to detect these events because of sequencing depth 
issues. Therefore, we feel the use of HPV capture technologies prior to sequencing is optimal 
because these sites will be enriched for and covered at a much higher depth. The issue with NGS 
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data is that analysis relies on high-quality fusion detection bioinformatics tools. Our group has 
attempted to use two previously available viral-host fusion callers, VirusSeq [30] and VirusFinder2 
[31, 32], with little success. These callers are not optimized for targeted capture sequencing data, 
and they provide too little information for downstream analysis of the sites. Therefore, we 
generated a novel bioinformatics pipeline “SearcHPV” specifically for HPV targeted capture data, 
which we showed to be accurate by Sanger sequencing validation. 
We performed HPV targeted capture sequencing on two HPV+HNSCC models and ran 
them through the SearcHPV pipeline. The first model we included was an HPV16+ cell line 
derived in our lab, UM-SCC-47, which has been assessed for HPV integration by multiple methods 
[7, 10, 33-35]. Given that the integration sites are well-described in this sample, we felt it was 
useful to determine the accuracy of our caller. SearcHPV called a total of six integration sites in 
UM-SCC-47 clustered within/near TP63, aligning with previous reports by our group and others 
[7, 10, 33-35]. Depending on the method used, the sites found within this gene differed slightly, 
but the majority of the sites we detected here have also been reported by one or more groups [7, 
10]. We detected one site that had not been previously reported within intron 10 of TP63, which 
we were able to validate independently by Sanger sequencing on the source DNA. There also two 
sites that were reported by others that we did not detect by SearcHPV [7, 35]. Despite these minor 
differences which could easily represent different clones that expanded in vitro in different 
laboratories, we feel that SearcHPV demonstrated its ability to detect a well-characterized 
integration site.  
The second model was an HPV16+ patient-derived xenograft (PDX) model (PDX-294R), 
which to our knowledge has not previously been investigated for HPV integration. SearcHPV 
called a high number of integration sites in this model (n=69), a large percentage of which fell into 
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known cellular genes, some with important roles in cancer. Although the majority of fusions 
detected were spread across the genome, we found a number of loci where integration events were 
clustered together surrounding cancer-related genes, including MYC, ZNF148 and FOXN2.  
Other groups have previously reported that integration is associated with large-scale 
structural variations, including deletions, duplications and rearrangements [5, 7]. In order to 
investigate this in our chosen models, we also subjected them to 10X linked reads sequencing. We 
found that approximately half of the integration sites we detected in PDX-294R were associated 
with large genomic duplications ranging from 50 to 100 kb, as were the integration sites within 
TP63 in UM-SCC-47. It is likely that these large genomic duplications were formed during the 
process of viral integration because they are consistent with previous reports that rolling circle 
amplification generates large HPV-human concatemers, resulting in large-scale duplications [7]. 
Based on the proximity of the integration sites to each other surrounding TP63 in UM-SCC-47, it 
is likely that these sites actually represent multiple fragments of one larger integration site that was 
established by rolling circle amplification. Similar events likely resulted in the multiple integration 
events detected within ZNF148, MYC and FOXN2 in PDX-294R, explaining why there were large-
scale duplications seen here as well. Other integration sites that were not associated with genomic 
duplications could have possibly integrated by a simpler method, such as direct integration [36].  
Future Directions 
Many questions about the impact of HPV integration on the progression of HNSCC still 
remain, but the rapidly developing set of tools available will allow us to address these unknowns. 
We demonstrated the utility of our HPV targeted capture-based pipeline SearcHPV with two 
HPV+ HNSCC models, and in the future, we plan to use this tool to assess the HPV integration 
sites within a larger cohort of samples, including a larger panel of HPV+ cell lines, additional 
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HPV+ PDXs from the National Cancer Institute, and approximately 300 HNSCC tumors we have 
sequenced thus far which we will continue to expand upon. We expect that the application of this 
pipeline in these large cohorts will help advance our understanding of the potential oncogenic 
mechanisms associated with this process by allowing for analysis of the patterns seen across many 
samples. This especially would allow for deeper investigation of the potential DNA repair 
mechanisms at play at these sites described in Chapter 4, as we have only been able to assess 
microhomology levels in a limited number of junctions.  
Pairing this targeted capture data with long-range DNA sequencing technologies, such as 
Nanopore sequencing, will allow us to better define the complex structural rearrangements caused 
by HPV integration and explain the structural basis of local amplification at integration sites. It 
would be particularly useful to run this parallel sequencing approach on the HPV+ cell lines, as 
these samples would have an abundance of tissue for downstream analyses and can be manipulated 
in knockout or knock-in experiments, although any tumor or PDX with fresh frozen tissue would 
also be great candidates for this approach. We have initiated this paired sequencing approach by 
performing Nanopore long-range whole genome sequencing of UM-SCC-47, for which analysis 
is ongoing. We expect long-range sequencing results from this cell line will help resolve the 
structure of the complex integration sites seen in TP63 which we can then use to understand the 
mechanism by which they were formed.  
Additional analysis of these samples at the RNA-level by traditional RNAseq or a more 
advanced approach on the Nanopore platform would also help clarify how integration affects 
tumor progression. This would allow for investigation of gene expression alterations near sites of 
integration but also genome wide. Importantly, long-range RNA sequencing would allow for 
resolution of the structure of viral-human fusion transcripts, which have been associated with 
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worse patient outcomes [18], but whose functions within the cell are entirely unknown. We have 
previously been limited in our ability to understand these functions due to a lack of a full sequence; 
however, obtaining the full sequence would allow us to tell if these fusion transcripts code for a 
fusion protein which could have novel oncogenic functions. Indeed, we have seen a truncated TP63 
protein in UM-SCC-47, which may in fact be a fusion protein [10]. Cloning of these full-length 
fusion transcripts into normal cells would also clarify what function they have and if they 
contribute to tumorigenesis or tumor progression.  
 Use of these technologies will also allow us to address other interesting questions that 
remain unanswered. Through our assessment of bilateral tonsillar tumors, it has become clear that 
integration events may be clonal within tumors and that cell populations with advantageous HPV 
integrations can expand. However, what makes one HPV integration advantageous over another is 
unclear. Evaluation of additional bilateral tumor pairs, as well as paired primary tumors and lymph 
nodes or distant metastases, by targeted capture and Nanopore long-range sequencing would allow 
us to explore the clonality of integration events. Additionally, single cell sequencing of fresh 
HPV+ tumors obtained from our surgical collaborators would allow us to explore the heterogeneity 
of integration sites at the single cell level. 
 Lastly, given the translational nature of our work, we ultimately care how this molecular 
process affects the patients we treat. In chapter 2, we observed that HPV+ OPSCC patients with 
HPV integration had improved disease-specific survival over those without HPV integration, 
which contradicts what has been previously reported. The underlying mechanism for this is unclear 
and requires further investigation. One possibility we plan to investigate in the future is differences 
in the antitumor immune response.  If HPV integration generates tumor neoantigens which can 
then be recognized as non-self by the host immune system, this could enhance antitumor immune 
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response. We will investigate if integration-positive vs integration negative patients have 
differential immune infiltration patterns and whether they can present these neoantigens for 
immune recognition. Our overarching goal has been, and continues to be, to make advances in the 
understanding of HPV-driven pathogenesis to lead to the development of novel biomarkers and/or 
treatment paradigms.  
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Appendix 1: Supplemental Tables 
Primer ID DIPS Primer Sequence Nested DIPS Primer Sequence 
HPV16-E6 5'-GTATTGCTGTTCTAATGTTGTTCC-3' 5'-GCAAAGTCATATACCTCACGTCG-3' 
HPV16-E1a 5'-ACGGGATGTAATGGATGGTTTTATG-3' 5'-AGGGGATGCTATATCAGATGACGAG-3' 
HPV16-E1b 5'-ATGTTACAGGTAGAAGGGCG-3' 5'-AGTCAGTATAGTGGTGGAAGTG-3' 
HPV16-E1c 5'-ACGCCAGAATGGATACAAAGACAAAC-3' 5'-ATGGTACAATGGGCCTACGATAATG-3' 
HPV16-E2a 5'-ACCCGCATGAACTTCCCATAC-3' 5'-TCAACTTGACCCTCTACCAC-3' 
HPV16-E2b 5'-GTGGACATTACAAGACGTTAGCCTTG-3' 5'-CATGGATATACAGTGGAAGTGCAG-3' 
HPV16-E2c 5'-CGTCTACATGGCATTGGACAGG-3' 5'-GATAGTGAATGGCAACGTGACC-3' 
HPV16-E5 5'-AGAGGCTGCTGTTATCCACAATAG-3' 5'-ATGTAGACACAGACAAAAGCAGC-3' 
HPV16-L2a 5'-GTACGCCTAGAGGTTAATGCTGG-3' 5'-CCAAAAAGTCAGGATCTGGAGC-3' 
HPV16-L2b 5'-CCACTTTACATGCAGCCTCACC-3' 5'-CTGTACCCTCTACATCTTTATCAGG-3' 
HPV16-L1 5'-ATCCACACCTGCATTTGCTGC-3' 5'-GCACTAGCATTTTCTGTGTCATCC-3' 
HPV18-E7 5'-CCAGAAGGTACAGACGGGGAG-3' 5'-CGGGTTGTAACGGCTGGTTTTATG-3' 
HPV18-E1a 5'-ATAGACAACGGGGGCACAGAG-3' 5'-GGGGCACAGAGGGCAACAAC-3' 
HPV18-E1b 5'-CCACCAAAATTGCGAAGTAGTG-3' 5'-TAATGGGAGACACACCTGAGTGGATAC-3' 
HPV18-E1c 5'-GAGGAAGAGGAAGATGCAGACAC-3' 5'-AAGATGCAGACACCGAAGGAAACC-3' 
HPV18-E2 5'-ACCTACAGGCAACAACAAAAGAC-3' 5'-CAGGCAACAACAAAAGACGGAAAC-3' 
HPV18-E5 5'-GGGGACGTTATTACCACAATATACACA-3' 5'-ACAGATGGCAAAAGCGGG-3' 
HPV18-L2a 5'-GAAATAGACACAGAGGTAGACGAAGGT-3' 5'-TCAAACCCAGACGTGCCAGTAAAC-3' 
HPV18-L2b 5'-ATGTTAATGTAGTGTCCACAGGCTCA-3' 5'-GCCGGGTTGTCATATGTAATTAAAGA-3' 
HPV18-L1 5'-CAGTATCTACCATATCACCATCTTCCAA-3' 5'-AACTGTGTTTTTAAGT-3' 








Sample Target F primer sequence R primer sequence 
BMT-251 
SGCZ exon 1- HPV16 L2 5’- CCACTTCGTTT AGTTGCGCT-3’ 
5’- AGGGGGTCTT 
ACAGGAGCAA-3’ 




UTP18 exon 1 – HPV16 L2 5’- GTTCCACGTG AGCGCCT-3’ 
5’- TAACCAACAG 
CAGAAGGACAA-3’ 
HPV16 L2 – UTP18 exon 2 5’- TCCTATAGTTCC AGGGTCTCCAC-3’ 
5’- CCACTTCTG 
AGTCACCCGAG-3’ 




NDST1 exon 2 - HPV18 E1 5’- ACTTCTGCTCT GCACAGGACC-3’ 
5’- CCGAAAGGG 
TTTCCTTCGGT-3’ 




DNAI1 exon 11 – HPV16 L1 5’- TGCTGATGAAT ACCGGGACC-3’ 
5’-GCACTAGCAT 
TTTCTGTGTCATCC-3’ 
NPAS3 exon 6 – HPV16 L1 5’- TTCCGAAACAG TCTCCATCTACC-3’ 
5’- ATCCACACCTG 
CATTTGCTGC-3’ 
UM-4068 HPV16 L1 – RLN1 exon 1 5’- GCACTAGCATTT TCTGTGTCATCC-3’ 
5’- TGCCACTGGT 
CTAGGTGTCT-3’ 
Table S2.2. Primers to amplify predicted fusion transcripts. 
Application Target F primer sequence R primer sequence Amplicon size (bp) 
qRT-PCR HPV16 E6 5’-TGCAATGTTTC AGGACCCAC-3’ 
5’-ATAGTTGTTT 
GCAGCTCTGTGC-3’ 72 
qRT-PCR HPV16 E7 5’-AGAACCGGACAG AGCCCATTACAA-3’ 
5’-TGTGCTTTGTAC 
GCACAACCGAAG-3’ 82 
qRT-PCR GAPDH 5’-CAAGAAGGT GGTGAAGCAG-3’ 
5’- TGAGCTTGAC 
AAAGTGGTCG-3’ 63 






RT-PCR HPV18 E6-E7 5’-TGTGCACGG AACTGAACACT-3’ 
5’-TGGAATGCT 
CGAAGGTCGTC-3’ 695 (E6FL-E7) 
RT-PCR HPV33 E6-E7 5’-GCCAAGCATT GGAGACAACT-3’ 
5’-TGGTTCGTAGG 
TCACTTGCT-3’ 652 (E6FL-E7) 

























































































a r NED - 
BMT-56 M 56 F 100 H 2006 Recurrence CRT ERB, CIS, CAR, 5FU a r DOD - 
BMT-280 F 64 N NA S 2008 T2N2bM0 CRT CIS r r NED - 
BMT-403 Data unavailable - 
BMT-412 M 50 C 31 L 2007 T2N0M0 RT NA r r NED - 
BMT-700 M 67 F 30 N 2009 T3N0M0 CRT ? r r DOD - 
BMT-1327 M 57 C 60 S 2012 T2N2bM0 CRT ERB r r DOD - 
UM-3884 M 55 N NA N 2015 T2N2bM0 CRT ERB r a DOD - 
UM-3917 M 54 N NA L 2016 T4N2cM0 CRT CAR, TAX r r NED - 
UM-3955 M 50 N NA N 2016 T4N2bM0 CRT CIS r r NED - 
UM-3962 M 56 F 42 N 2016 T3N2cM0 surgery + CRT CIS r r NED - 
UM-3989 M 62 N NA L 2016 T4aN2cM1 palliative RT NA r a DOD - 
UM-4028 M 66 F 11 L 2016 T4aN2cMx CRT, then immunotherapy CIS r a DOD - 
UM-4093 M 55 F 18.5 N 2017 T1N1M0 RT NA r r NED - 
BMT-233 M 79 C 60 H 2009 T2N0M0 CRT DOC a a NED + 
BMT-319 Data unavailable + 
BMT-322 F 69 N NA N 2005 T2N0M0 CRT CIS a a DOD + 
BMT-344 M 72 F 10 L 2007 T4N2bM0 CRT ERB, CIS, GEM, DOC a r DOD + 
BMT-400 F 65 N NA N 2007 T2N1M0 CRT ? r r NED + 
BMT-402 M 60 F 40 H 2007 T3N0M0 CRT ? ? ? DUC + 
BMT-404 M 81 F 40 S 2007 T2N1M0 CRT ERB r r NED + 
BMT-411 M 46 N NA S 2008 T2N2M0 CRT CIS r r NED + 
BMT-427 F 85 F ? S 2009 T3N0M0 CRT ERB r r NED + 
UM-3940 F 66 F 15 N 2016 T1N1M0 surgery + RT NA r r NED + 
UM-3948 M 59 C 60 L 2016 T3N2bM0 surgery NA r r DUC + 
UM-4067* F 67 F 12.5 H 2017 T3N1M0 surgery + CRT CIS r r NED + 
BMT-251 F 87 F 10 N 2009 T2N0M0 CRT ERB a r NED + 
BMT-323 M 61 C 100 H 2005 T3N2cM0 CRT TPF a a DOD + 
BMT-331 M 62 N NA N 2006 T1N2cM0 CRT ERB r r NED + 
BMT-1159 M 51 F 10 L 2010 T2N1M0 CRT ? r r NED + 
UM-3898† M 53 F 25 L 2016 T4N0M0 surgery NA r r DUC + 
UM-3938 M 51 F 22 H 2016 T4aN0Mx CRT CAR r r NED + 
UM-3954 M 74 N NA N 2016 T1N1M0 surgery NA r r NED + 
UM-4011 M 63 N NA N 2016 T1N2bM0 surgery + RT NA r r NED + 
UM-4068 M 70 N NA N 2017 T2N1M0 surgery  NA r r NED + 
Table S2.4. Patient clinical information. Oropharyngeal SCC unless otherwise indicated by *(nasopharyngeal SCC) or †(oral 
cavity SCC).  
Abbreviations:  LRF, locoregional failure. DM, distant metastasis. M, male. F, female. N, never. F, former. C, current.  NA, not 
applicable. H, heavy. L, light. S, social. CRT, chemoradiation. RT, radiation. ERB, erbitux. CIS, cisplatin. CAR, carboplatin. TAX, 
taxol. 5FU, fluorouracil. DOC, docetaxel. TPF, docetaxel+cisplatin+fluorouracil. GEM, gemcitabine. a, yes. r, no. DOD, died of 
disease. DUC, died of unrelated cause. NED, alive with no evidence of disease. ?, unknown. -, negative. +, positive. 
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LAMA3 Exon 1 5’-CATATCCCC GGCTGCGCTA-3’ 
5’-GCCAGGTTGAA 
GTAAGTCGGG-3’ 280 - 
LAMA3 Exon 2 5’-CATCCTGTCAC CAATGCCATC-3’ 
5’-CCAAGGTGAGG 
TTGACTCTGTT-3’ 97 97 
LAMA3 Intron1:68 





GACAAAAGCAGC-3’ 260 260 
CD36 Exon 4 5’-TGGGTTAAA ACAGGCACAGAA-3’ 
5’-ACTTGAATGTTGCT 
GCTGTTCA-3’ 95 - 
CD36 Exon 5 5’-CGCTGAGGAC AACACAGTCT-3’ 
5’-GCCACAGCCA 
GATTGAGAAC-3’ 111 - 
CD36 Exon 6 5’-TGTTCCAAGTCA GAACTTTGAGAG-3’ 
5’-CAGGGTACGGAA 
CCAAACTCA-3’ 75 - 
CD36 Exon5-6_6-7 5’-GGCAGCTGC ATCCCATATCT-3’ 
5’-CCATCTGCAGTA 
TTGTTGTAAGGA-3’ - 204 
HPV16 L2 –  




AATTTTTAAGGCCA-3’ - 212 
HPV16 E2 - 




GTACCAGTA-3’ - 160 























Loci Caller F primer seq R primer seq 
Size 
(bp) 
1 MYC SRCH/VS 5’-TGTAACCTTGCTAA AGGAGTGA-3’ 
5’-TGCACCACCAA 
AAGGAATTGT-3’ 79 
2 RHBDL3 SRCH 5’-ATTATCCACACCTG CATTTGCT-3’ 
5’-GTGCTGACATTGG 
GTATGGGG-3’ 145 
3 VIRMA SRCH/VF2 5’-AGGGATGTCCA ACTGCAAGTA-3’ 
5’-CAGGAACAGCT 
CAGAAGCAT-3’ 93 
4 CCDC59 SRCH/VF2 5’-TGCCACAATACAA GCTTTAGTCA-3’ 
5’-GGGTGGTTGCAG 
TCAGTACA-3’ 74 
5 ANKS1B SRCH 5’-CACATGCGCCTA GAATGTGC-3’ 
5’-TGAGGTGGTGTGTT 
AAGTAACCT-3’ 99 
6 ZFP69 SRCH 5’-GGCGTGCTTTT TGCTTTGC-3’ 
5’-TACTTTAAGCCCATC 
CAATGAATTT-3’ 73 
7 MTSS1 SRCH/VS/VF2 5’-TTCAGGTCGAGAC CCTTGTC-3’ 
5’-CACTTGCTCCTGTA 
AGACCCC-3’ 97 
8 DDI2 SRCH/VF2 5’-AGGCCAACTAAAC ACCACGG-3’ 
5’-ACAATTGAAAAAG 
CCACTATCGG-3’ 76 
9 ADGRF2 SRCH/VF2 5’-TCCTCACTCCCACCT AACCG-3’ 
5’-TTCGGTTACGCCCTT 
AGTTTT-3’ 103 
10 NRXN3 SRCH 5’-CCAGGTAGACATAGA TCCTTGACC-3’ 
5’-ACTGCAAATTTA 
GCCAGTTCAAA-3’ 82 
11 ZNF148 SRCH/VS/VF2 5’-TGCATCCACAACAT TACTGGC-3’ 
5’-AGCATGATTCTG 
AAGGAGGGA-3’ 134 
12 ZNF148 SRCH 5’-ACACAGACAAAA GCAGCGGA-3’ 
5’-CCATTGACGTGT 
CAAGGCTC-3’ 97 
13 SPATA19 SRCH 5’-GCAGCCTCTG CGTTTAGGT-3’ 
5’-CAGGTAGGGTGG 
GGGTGACT-3’ 87 
14 ARGHGEF12 SRCH 5’-TGGTTACCTCTGAT GCCCAAA-3’ 
5’-TTGCTGTCTAGA 
TTCCCGCC-3’ 92 
15 Intergenic (6) SRCH/VF2 5’-AGTTGGTTACCCCA ACAAATGC-3’ 
5’-AGAGGAGAATA 
AAATAGCCAGAGCA-3’ 70 
16 Intergenic (3) SRCH 5’-ATGCAAAGGCAGC AATGTTAGC-3’ 
5’-TGGTTATACAGA 
GCCAGCCC-3’ 130 
17 Intergenic (6) SRCH 5’-GATGCTGGAC GCTGCAAAAG-3’ 
5’-TGGCGTGTCTCC 
ATACACTT-3’ 91 
18 Intergenic (19) SRCH 5’-CACAGACGACT ATCCAGCGA-3’ 
5’-TGGCTCACGCCT 
ATTATCACT-3’ 90 
19 Intergenic (5) SRCH 5’-TGGCCACTAATG CCCACAC-3’ 
5’-AATCTCAGCAACAG 
AAAGGGGG-3’ 115 
20 Intergenic (3) SRCH 5’-TCAAATAGCTTCC ACCTTGGCT-3’ 
5’-TCTTCTTTAGGTGC 
TGGAGGTG-3’ 126 
21 Intergenic (5) SRCH 5’-GAACAATTGTGTT ATTTACTGGGGA-3’ 
5’-AACTTAGTGGTG 
TGGCAGGG-3’ 123 
22 Intergenic (3) SRCH 5’-GGCACTGGTCAA GGCATTTG-3’ 
5’-TGGGGGAGGTTG 
TAGACCAA-3’ 112 
23 Intergenic (3) SRCH 5’-AGACCAAAATTCCA GTCCTCCA-3’ 
5’-GGCACTGGTCA 
AGGCATTTG-3’ 99 
24 Intergenic (5) SRCH/VF2 5’-ACATTTTCACCAA CAGCACCAG-3’ 
5’-AAACCTGCTATTGA 
GACCTACTGC-3’ 83 
25 Intergenic (8) SRCH 5’-GGGAGAGGGTGTT AGTGAAACT-3’ 
5’-TCCCCACAACAG 
TACTAAAACGTA-3’ 96 
26 Intergenic (8) SRCH/VS 5’-GCATGTTCATGGGG AATGGTT-3’ 
5’-ACTGAGTCCCC 
CAATTTGCT-3’ 104 
27 Intergenic (13) SRCH/VS/VF2 5’-GCTTCAGCATT CCACGATGC-3’ 
5’-TCCTCCCCATGT 
CGTAGGTA-3’ 109 
28 Intergenic (1) SRCH 5’-GACCAAAATTCCA GTCCTCCA-3’ 
5’-GCTCCAATTGGGCA 
TTTTTCAG-3’ 88 
29 Intergenic (3) SRCH 5’-ATCTTCTAGTG TGCCTCCTGG-3’ 
5’-CTCCAGCAGAG 
ATGTTCCAGA-3’ 106 
30 Intergenic (6) SRCH/VF2 5’-ACACATTGTTGC ACAATCCTTTACA-3’ 
5’-TCTGTCTGAGCA 
TTCACAACT-3’ 101 
31 Intergenic (3) SRCH 5’-TCGGAATGACT CGCAGGTG-3’ 
5’-GAAGGGCCCAC 
AGGATCTAC-3’ 139 
32 Intergenic (4) SRCH 5’-CAGTGGCACG CCTAGGATTA-3’ 
5’-AGCTCTTAACCA 
GTTACTAATGGAA-3’ 96 
Continued on next page 
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33 Intergenic (18) SRCH/VS/VF2 5’-CAATAGAGTGAG TGCTCCATAACT-3’ 
5’-GCTTATGCAGCA 
AATGCAGGT-3’ 147 
34 Intergenic (13) VS 5’-GTGGACCGGT CGATGTATGT-3’ 
5’-CCTCTTGCTTAC 
CCACCCCT-3’ 80 
35 Intergenic (13) VS 5’-GTGTGACTCTA CGCTTCGGT-3’ 
5’-ACCTTGGGGTG 
TTACAAGGC-3’ 199 
36 Intergenic (2) VS 5’-CGACCCATACCA AAGCCGT-3’ 
5’-GGGCCACACTT 
GGAGTAGTAA-3’ 174 
37 Intergenic (2) VS 5’-CCCTGCCACACC ACTAAGTT-3’ 
5’-CTTGGGCCACA 
CTTGGAGTA-3’ 167 
38 VIRMA VS 5’-AACCTCCCATC ACTGACCCA-3’ 
5’-AACCAGCCGCTGT 
GTATCTG-3’ 250 
39 MTSS1 VS 5’-AGGAAGCGTT CCCTGCAAAA-3’ 
5’-TGAGGTGGTGG 
GTGTAGCTT-3’ 242 
40 Intergenic (18) VS 5’-AGGATAACAACTT TTGCAGCGT-3’ 
5’-TTCCTCCCCATG 
TCGTAGGT-3’ 179 
41 MTSS1 VS 5’-TGCCTGATCG CATTCCAAGT-3’ 
5’-GCATGACACAAT 
AGTTACACAAGC-3’ 193 
42 TP63 SRCH 5’-AGGACTGAGCC TGATTCTGC-3’ 
5’-TCTGCATCATCTT 
TAAACTGCACA-3’ 103 
43 TP63 SRCH 5’-AGGAGGGTAGG TCAGAAACCA-3’ 
5’-TTCCTCCCCATGT 
CGTAGGT-3’ 110 
44 TP63 SRCH 5’-TGGCTCCCTTCC AACACAAG-3’ 
5’-TTACTGGCGTGC 
TTTTTGCT-3’ 122 
45 Intergenic (3) SRCH 5’-CAGCAAGGCAA AGAAGAACCAG-3’ 
5’-CAGAGGCTGCTG 
TTATCCACAA-3’ 99 
46 TP63 SRCH 5’-AACCAGCATGGA AACAAGGGAA-3’ 
5’-TACAACGAGCAC 
AGGGCCAC-3’ 123 
Table S4.1. HPV-human junction validation primers. Intergenic sites of integration are listed as “Intergenic 
(chromosome #).” Each primer set was run multiplexed with GAPDH control primers: F seq 5’-
GAGTCAACGGATTTGGTCGT-3’ R seq 5’-GGAGGCATTGCTGATGATCT-3’. 







HumPos Site HPVPos SP PE Conf 
chr3:189596814 TP63 2379;2379 694 926 high 
chr3:189597479 TP63 2915;3000 142 167 high 
chr3:189601562 TP63 5807 172 190 high 
chr3:189607491 TP63 5678 135 168 high 
chr3:189612850 TP63 2855 7784 10321 high 
chr3:189620989 Int 3091 106 130 high 
Table S4.2: Detailed integration sites in UM-SCC-47 called by SearcHPV. 
Abbreviations:  HumPos, position of integration site in the human genome.  Int, intergenic. HPVPos, position of 
integration site in the HPV genome. SP, number of split reads. PE, number of paired-end reads. Conf, confidence 
of integration site.  
 123 
HumPos Site HPVPos SP PE Conf 
chr1:101055413 Int 6972 5 13 high 
chr1:15946207 DDI2 6841;6841 5 11 high 
chr1:224074048 Int 5935;2482 6 16 high 
chr1:40952566 ZFP69 3055 2 3 low 
chr2:25619085 DTNB 1710 3 7 high 
chr2:33141307 LINC00486 847 1 9 low 
chr2:48532381 Int 2618;1485 403 1330 high 
chr2:48549010 FOXN2 2322 6 6 high 
chr2:48677465 PPP1R21 3050 2 9 low 
chr2:63781782 WDPCP 5819 4 10 high 
chr3:125014302 ZNF148 4063 3 8 high 
chr3:125062101 ZNF148 3029 4 8 high 
chr3:125086159 ZNF148 3080;3009 27 43 high 
chr3:125100716 ZNF148 3612 9 14 high 
chr3:125102495 ZNF148 5933 12 49 high 
chr3:125114197 Int 603 2 7 low 
chr3:125120338 Int 5980;1440 697 1541 high 
chr3:125124585 Int 3960 3 4 high 
chr3:125124720 Int 3960 1 6 low 
chr3:125124863 Int 3960 1 4 low 
chr3:125127659 Int 962 3 3 high 
chr3:125139102 Int 5933 8 45 high 
chr3:125143564 Int 4726 5 7 high 
chr3:125150392 Int 943 3 5 high 
chr3:125202167 SNX4 7753 6 6 high 
chr3:168565534 Int 1677 1 4 low 
chr3:182496148 Int 6025 4 10 high 
chr4:16933044 Int 3973 8 8 high 
chr4:179530965 Int 1294 5 12 high 
chr4:181953470 Int 5644;3547 3 3 high 
chr5:122086492 Int 5087 4 6 high 
chr5:165910098 Int 5552 5 11 high 
chr5:19010612 RP11-124N3.3 2594 2 6 low 
chr5:35396304 Int 5098 2 11 low 
chr6:104216242 Int 1166 2 5 low 
chr6:104246619 Int 5736 3 8 high 
chr6:12630462 Int 904 1 6 low 
chr6:47640614 GPR111 6994 6 17 high 
chr6:9560308 Int 982 2 4 low 
chr7:126441830 GRM8 4099;3781 15 23 high 
chr7:45348769 Int 1536 3 6 high 
chr8:125728800 MTSS1 3593;3647 851 2647 high 
chr8:128693537 Int 547 6 9 high 
chr8:128747276 MYC 6647;793 1 765 low 
chr8:128747548 MYC 6647;821 1173 3438 high 
chr8:128752628 MYC 4535 13 16 high 
chr8:95537452 VIRMA 4898;2599 26 74 high 
chr9:115989198 SLC31A1 1307 4 4 high 
chr9:13135999 MPDZ 3458 4 6 high 
chr9:98459616 RP11-180I4.2 911;815 612 1644 high 
chr9:98459788 RP11-180I4.2 940;815 578 1876 high 
Continued on next page 
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chr10:29399148 Int 1359 4 6 high 
chr10:4287865 Int 2570 20 54 high 
chr11:120297939 ARHGEF12 5662 16 26 high 
chr11:133712310 SPATA19 3088 3 4 high 
chr11:27916059 Int 5607 4 18 high 
chr12:132188289 Int 4597 3 4 high 
chr12:41882591 PDZRN4 5755 4 7 high 
chr12:82739625 CCDC59 436;3463 10 24 high 
chr12:99239651 ANKS1B 1972 2 4 low 
chr13:72999194 Int 1875;1875 170 248 high 
chr13:73006471 Int 273;5807 372 949 high 
chr13:73018748 Int 5039 3 4 high 
chr14:79246541 NRXN3 5678;5779 5 10 high 
chr15:55379458 RP11-548M13.1 7512;7512 40 82 high 
chr17:30607816 RHBDL3 5169 3 4 high 
chr17:66394369 ARSG 1305;1296 4 8 high 
chr18:40967390 Int 5671;5160 273 731 high 
chr19:8795646 Int 2585 4 4 high 
Table S4.3: Detailed integration sites in PDX-294R called by SearcHPV. 
Abbreviations:  HumPos, position of integration site in the human genome.  Int, intergenic. HPVPos, position of 
integration site in the HPV genome. SP, number of split reads. PE, number of paired-end reads. Conf, confidence 
of integration site. 
 
Name UM-SCC-47 PDX-294R 
GEMs Detected 1,397,989 1,497,818 
N50 Linked-Reads per Molecule (LPM) 83 11 
Mean DNA per GEM 453,260 bp 727,420 bp 
SNPs Phased 98.90% 97.80% 
Longest Phase Block 28,941,610 bp 3,891,048 bp 
N50 Phase Block 7,568,760 bp 500,018 bp 
DNA in Molecules >20kb 94.30% 48.90% 
DNA in Molecules >100kb 39.80% 4.23% 
Corrected Estimated of DNA Loaded 1.06 ng 1.71 ng 
Large Structural Variant Calls 444 126 
Short Deletion Calls 4,398 4,665 
Number of Reads 1,047,322,794 1,018,363,956 
Median Insert Size 362 bp 362 bp 
Mean Depth 45.2 X 39.5 X 
Zero Coverage 0.14% 0.40% 
Mapped Reads 95.40% 87.40% 
PCR Duplication 4.86% 5.92% 
Q30 bases, Read 1 89.40% 88.10% 
Q30 bases, Read 2 86.10% 85.70% 
Table S4.4. Linked read sequencing statistics. 
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DSS by Age at Diagnosis
Younger (<62.9)
Older (>62.9)
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Figure S2.1. Kaplan Meier curves separated by clinical variables. A. Age (above vs below 




















DSS by Any E6E7 Transcript Expression
E6E7 Transcript +
E6E7 Transcript -

















Figure S2.2. Kaplan Meier curves separated by A) any E6E7 transcript expression 
determined by qRT-PCR or RT-PCR and B) E6 alternate transcript expression.














DSS by E6 Alternate Transcript Expression
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E6* only
No E6FL or E6*
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Figure S4.1: PCR validation gel electrophoresis. Top band of each row shows GAPDH (535 bp), bottom
bands represent predicted HPV-human junctions (ranging from 70-250 bp). Red boxes demonstrate bands that
appeared at the correct molecular weight and were validated by Sanger sequencing.
A. B.UM-SCC-47 PDX-294R
Figure S4.2: Linked read SNP phase plots for UM-SCC-47 (A) and PDX-294R (B) genomes. Alternating colors represent
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